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Summary 
 Natural killer (NK) cells are able to attack and destroy tumorous or virally infected 
cells without prior sensitization. The processes that regulate their activation and function are 
still incompletely understood. NK cells do not exress a single clonal receptor like T-cells but 
many different activating and inhibitory receptors. Most of the inhibitory receptors bind to 
MHC I or related molecules. Some activating receptors recognize ligands induced upon cell 
stress or transformation. One group of inhibitory receptors on NK cells is constituted by the 
NKG2 family. Some of these receptors form antithetic pairs. That means, they recognize the 
same ligands but signal in a contrary fashion. One of the most important NKG2 receptors is 
NKG2D. For this receptor an antithetic counterpart has not been described yet.  
One part of this thesis included the identification of a possible inhibitory counterpart 
for NKG2D. Data base searches retrieved the cDNA for CLEC12B. Characterization of the 
receptor lead to the result that it did not bind the known NKG2D ligands and was not 
expressed on NK cells. Nevertheless, it is able to confer inhibitory signaling via the 
recruitment of the tyrosine-phosphatases SHP-1 and SHP-2. Expression of the inhibitory 
receptor CLEC12B was detected on monocyte-derived macrophages.  
Another important group of activating receptors is constituted by the natural 
cytotoxicity receptors (NCR). They have been implied in antiviral defense and in the 
recognition of malignant cells. Although the ligand remains unknown it is still possible to 
detect it by applying functional assays and staining methods using soluble fusion proteins. 
The role of the NCR ligands has up to now not been examined in human cytomegalovirus 
(HCMV) infection. Fusion protein staining and functional data presented in this thesis 
suggest that the NCR ligands are downregulated from the cell surface. This might constitute 
a new immune evasion mechanism of HCMV. It was discovered that this process is mediated 
by a viral gene product that is expressed de novo upon infection during the immediate early 
or early phase of infection. The creation of viral deletion mutants helped to exclude non-
essential regions of the HCMV genome. Immunofluorescence staining with fusion proteins 
showed that the ligand is held back in intracellular compartments. For further research the 
elucidation of the NCR ligands is vitally important. Heparan sulfate structures have been 
postulated to function as ligands but these results are debated. In this thesis, it was 
established that heparan sulfate is not the functional ligand for NKp30. The putative ligand 
was found to involve a proteinacious component that is not GPI-anchored. It was tried to 
identify the NKp30 ligand with the help of a genomic siRNA library. Cells expressing the 
NKp30 ligand were transduced with the library and selected for cells with an NKp30 negative 
phenotype. The siRNAs were rescued from the cell population, amplified and analyzed via an 
affimetrix genechip. The results show the enrichment of some interesting transmembrane or 
secreted proteins as possible candidates that might function as ligand for NKp30.
Zusammenfassung 
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Zusammenfassung 
 Natürliche Killer (NK) Zellen sind in der Lage transformierte oder mit Viren infizierte 
Zellen ohne vorherige Sensibilisierung zu erkennen und zu lysieren. Um diese Aufgabe 
erfüllen zu können, verfügen NK-Zellen über verschiedene Rezeptoren mit aktivierender oder 
inhibierender Funktion. Die meisten inhibitorischen Rezeptoren binden an MHC I Moleküle. 
Einige der aktivierenden Rezeptoren erkennen Liganden, die nach Zellstress oder 
Transformation exprimiert werden. Eine wichtige Gruppe der NK-Zell Rezeptoren ist die 
NKG2-Familie. Manche dieser Rezeptoren bilden antithetische Paare, die dieselben 
Liganden erkennen, aber gegensätzliche Signale auslösen. Einer der wichtigsten 
aktivierenden Rezeptoren dieser Gruppe ist NKG2D, für den bisher noch kein inhibitorischer 
Gegenpart bekannt ist. Ein Teil dieser Arbeit zielte darauf ab, einen potentiellen 
inhibitorischen Gegenpart für den NKG2D-Rezeptor zu identifizieren. Eine Datenbanksuche 
identifizierte die cDNA von CLEC12B als möglichen Kandidaten. Die Charakterisierung 
dieses Rezeptors zeigte, daß er trotz Homologie zu NKG2D keinerlei Affinität für die 
bekannten NKG2D Liganden besitzt und nicht in NK-Zellen exprimiert wird. Allerdings ist er 
in der Lage inhibitorische Signale durch die Rekrutierung der Tyrosin-Phosphatasen SHP-1 
und SHP-2 auszulösen. Die Expression von CLEC12B konnte schließlich auf aus Monozyten 
generierten Makrophagen festgestellt werden.  
Eine weitere Gruppe ist die Familie der Natural Cytotoxicity Receptors (NCR) mit den 
Rezeptoren NKp30, NKp44 und NKp46. Obwohl ihre Liganden bisher noch unbekannt sind, 
ist es möglich sie mit der Hilfe funktioneller Experimente und löslicher Fusionsproteine zu 
detektieren. Über die Rolle des NKp30 Liganden während einer Infektion mit humanem 
Cytomegalievirus (HCMV) ist bisher nichts bekannt. Über Färbungen mit Fusionsproteinen 
und funktionelle Experimente konnte gezeigt werden, daß im Zuge einer HCMV Infektion die 
Expression des NKp30 Liganden unterdrückt wird. Dieser Prozess wird durch ein virales 
Genprodukt ausgelöst, das de novo während der frühen Infektionsphase exprimiert wird. 
Über die Generierung von Deletionsmutanten konnten große Bereiche des HCMV Genoms 
mit nicht-essentiellen Genen ausgeschlossen werden. Immunfluoreszenz-Färbungen mit 
Fusionsproteinen zeigten, dass die Liganden von NKp30 in intrazellulären Kompartimenten 
zurückgehalten werden. Für weitere Forschung ist die Identifikation der NCR Liganden 
unumgänglich. Es wurde ein siRNA screen etabliert, um den NKp30 Liganden zu 
identifizieren. Zellen, die den NKp30 Liganden exprimieren, wurden mit einer siRNA 
Bibliothek transduziert und auf einen NKp30 negativen Phänotyp selektioniert. Die siRNAs 
wurden aus der entstandenen Zell-Population isoliert, amplifiziert und über einen affimetrix 
gene chip analysiert. Als Resultat ergaben sich siRNAs, die gegen einige interessante 
Transmembranproteine gerichtet sind. Diese möglichen Kandidaten stellen die Basis für 
weitere Untersuchungen dar. 
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I. Introduction 
 
I.1 Natural killer (NK) cell biology 
 Our immune system is a sophisticated network of highly specialized cells that combat 
infections and cancer. Numerous cell types have evolved fulfilling distinct functions in this 
challenge. NK cells constitute a part of the cells found in the thick of the fray, secreting pro-
inflammatory cytokines and destroying infected or transformed cells.  
 NK cells were first described in 1975 as having the ability to lyse allogeneic tumor 
cells in mice without prior sensitization (Herberman et al., 1975a; Herberman et al., 1975b; 
Kiessling et al., 1975a; Kiessling et al., 1975b). Later on it became clear that NK cells were 
also responsible for the phenomenon of F1 hybrid resistance (Kiessling et al., 1977). 
Therefore, the term ‘natural cytotoxicity’ was coined and used to describe this particular cell 
type that was, unlike the cells of the adaptive immune system, a ‘natural killer’ (Lanier et al., 
1986). Additionally, these cells were discovered to play an important role as a first line of 
defense against viral infections and other intracellular pathogens. Human NK cells are 
historically defined as CD56+ and CD3- (Cooper et al., 2001) but new data suggest that a 
definition as NKp46+ and CD3- would be more serviceable over species barriers (Walzer et 
al., 2007a).  
 NK cells constitute 5-15% of the human peripheral blood mononuclear cells (PBMC) 
population and up to 5% of the whole lymphocyte population in lymph nodes. Additionally, 
NK cells can be found throughout most tissues including liver, spleen and lung. A specialized 
type of NK cells plays a very important role in the decidua during pregnancy (Tabiasco et al., 
2006). Although NK cells show strong similarities with T-cells, they are classified as innate 
immune cells. In contrast to cells of the adaptive immune system which have to be primed by 
other immune cells, NK cells can act without prior stimulation. This characteristic makes the 
innate immune cells the first line of defense against pathogenic intruders until the adaptive 
immune response is able to step in. This point of view led to the assumption that the innate 
immune system was evolutionary old-fashioned, just a remainder of early defense 
mechanisms and a precursor of the adaptive immune system. By now this perception has 
changed. Mice and humans that lack innate immune cells are not able to control infections 
long enough to activate the adaptive immune response. They die before these specialized 
cells are ready to defend them (Mandell et al., 2000). Both parts of the immune system are 
equally important and work hand in hand to fight infections and cancer.  
 Human NK cells can be divided into two different subsets according to their 
expression of the surface markers CD56 and CD16. About 90% of the NK cell population 
show a CD56dim phenotype while 10% are CD56bright. CD56bright cells do not express CD16 
and CD56dim cells are high in CD16 expression (Cooper et al., 2001). Both subsets have 
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been reported to fulfill distinct functions. While the CD56dim subset is responsible for the lysis 
of tumors and virally infected cells, CD56bright NK cells are producers of important cytokines, 
including interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) (Biron et al., 1999). These 
cytokines are crucial for the initiation of a protective T-cell response against pathogens and 
cancer. Furthermore NK cells exist in a closely intertwined relationship with dendritic cells 
(DCs) including mutual activation based on cytokine production and cell-cell contacts (Degli-
Esposti and Smyth, 2005). Thus, based on their lineage relationships, receptor repertoire, 
and effector functions, NK cells appear to be a transitional cell type bridging the innate and 
adaptive immune systems. Their importance becomes clear in patients born without NK cells. 
These patients suffer from recurrent illnesses and have particular problems in controling 
herpesviral infections despite their functional adaptive immune response (Biron et al., 1989).  
 NK cells have evolved much later than the first simple phagocytic cells. Although the 
genes for the lytic enzymes perforin and granzyme and the transcription factors that control 
their expression can be found in rather simple organisms like fish (Spits et al., 1998) the 
receptor families or signaling adaptors that characterize NK cells seem to have arisen after 
the mammalian branching. This finding puts NK cells onto the same evolutionary step as T-
cells. In this context it seems that the cytolytic machinery used by NK cells is very old, their 
recognition mechanisms have only evolved recently (Walzer et al., 2007b).  
 NK cell development takes place in the bone marrow (Colucci et al., 2003). They 
arise from CD34+ common lymphoid progenitor cells. Although NK cells are part of the innate 
immune system they do not descend from myeloid progenitor cells which can give rise to 
dendritic cells or monocytes. Instead they share a common progenitor with T-cells. NK cell 
development is dependent on the presence of interleukin-15 (IL-15) or IL-2. In contrast to B- 
and T-cells, NK cells do not undergo somatic recombination. A fact which has been 
demonstrated by the existence of NK cells in RAG1 and RAG2 knockout mice (Hackett et al., 
1986). NK cells do not require a functional thymus for development but an intact bone 
marrow. Furthermore, recent data suggest that part of the NK cell developmental pathway 
takes place in the parafollicular T-cell rich regions of secondary lymphoid organs (Freud and 
Caligiuri, 2006).  
 NK cells do not only share a common progenitor with T-cells, they also show 
interesting functional similarities. Various receptors that have been identified on NK cells can 
also be found on T-cells, although with potentially different functional outcome. For example 
the family of SLAM-related-receptors (SRR) is found on both NK and T-cells. But while 
receptors like 2B4 and NTB-A can activate IL-2 stimulated NK cells to lyse target cells, they 
serve a costimulatory purpose in the T-cell activation process (Bhat et al., 2006). Another 
similarity is that the mechanism employed by NK cells to lyse target cells resembles that of 
cytotoxic T lymphocytes. Both cell types have preformed granules in their cytoplasm which 
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contain toxic enzymes like perforin, granzymes and granulysin. Upon contact with a 
susceptible cell, the NK cell polarizes its cellular machinery including the granules into the 
direction of the target cell. Then the granules fuse with the outer membrane of the NK cell 
and their contents are released into the synaptic cleft between the killer cell and its target. 
According to the current view, perforin molecules form a pore in the target cell membrane 
which enables granzymes to diffuse into the cytoplasm of the attacked cell and initiate 
apoptotic processes. Further mechanisms employed by NK and T-cells include induction of 
apoptosis via TRAIL or engagement of the Fas receptor on the target cell surface via the Fas 
ligand (Lieberman, 2003).  
NK cell activity has to be inhibited by healthy tissue to avoid damage. This is 
accomplished by the expression of MHC I molecules. NK cells express inhibiting receptors 
that recognize MHC I.  Here we find yet another similarity but also a striking difference to T-
cells. Both cell types have receptors for MHC I molecules but while T-cells monitor which 
peptide is presented through the MHC I molecule, NK cells just bind MHC I no matter which 
peptide is presented. If in the course of a viral infection or tumorigenesis MHC I is lost from 
the cell surface in an attempt to escape T-cell surveillance, the NK cells can be activated to 
lyse this MHC I low target cell. The same can happen when during a transplantation process 
the MHC I alleles of the transplant donor do not match the recipient’s. NK cells are not 
inhibited by ‘foreign’ MHC I and thus able to lyse the respective target cell (Karre et al., 
1986). This so called ‘missing self hypothesis’ as shown in fig. 1 has long been the central 
dogma of NK cell research. However, NK cells are not overreactive in humans or mice 
deficient in expression of MHC I or associated proteins (Bix et al., 1991; Furukawa et al., 
1999; Hoglund et al., 1991; Vitale et al., 2002) but rather hyporesponsive to MHC I deficient 
targets. Therefore it seems that the recognition of MHC I by NK cells is not a static system 
like the conserved pattern recognition receptors of other innate immune cells but more like a 
flexible machinery acquired during NK cell generation in the host. In the course of their 
development, NK cells ‘learn’ which MHC I alleles are expressed as self in their particular 
surrounding. There are fitting inhibitory receptors on NK cells for the many different possible 
MHC I alleles. These different receptor alleles seem to be expressed in a stochastic fashion 
on the developing NK cell. NK cells that happen to lack expression of an inhibitory receptor 
that fits at least one of the MHC I molecules expressed as self become hyporesponsive. The 
mechanisms of this process are still debated but summarized under the term ‘licensing’. It 
has been shown that in the blood of healthy donors NK cells can be found that do not 
express a single one of the known MHC I binding inhibitory NK cell receptors. These NK 
cells, in contrast to the ones that do express receptors for fitting MHC I molecules, are 
hyporesponsive as well (Anfossi et al., 2006). Hence, potentially self-reactive NK cells are 
rendered harmless during their development before they can cause any damage. 
Introduction 
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Fig 1: The missing self hypothesis. NK cells express inhibitory receptors for self MHC I molecules. 
Are these engaged upon contact with a potential target cell, the NK cell is inhibited and the target cell 
spared fom lysis. If MHC I molecules are downregulated upon infection or tumorigenesis or don’t 
match after a transplantation, the inhibitory receptors are no longer engaged and the NK cell can be 
activated to lyse the target cell. 
 
 The missing self hypothesis and the licensing mechanism are still not the ultima ratio 
to the regulation of NK cell activity. In recent years it has become quite clear that activating 
receptors are involved in the regulation of NK cell activity as well. A new term called ‘induced 
self’ has been coined to describe this new concept (Watzl, 2003). Target cells that do not 
express any functional NK cell ligands neither inhibiting nor activating are not attacked at all, 
for example cells from foreign species like Drosophila melanogaster. Stimulating ligands are 
needed to fully activate an NK cell. Some of these molecules are constitutively expressed on 
target cells, some only upon infection or cell stress. High expression of these ligands can 
provide an override mechanism and lead to lysis of the target cell despite self-MHC I 
presentation (Regunathan et al., 2005).  
 As displayed in fig. 2, it seems that the gist of the matter of NK cell regulation is a 
tightly controlled balance of inhibiting and activating stimuli. This balance can be further 
influenced for example through the presence of proinflammatory cytokines and other soluble 
agents. Additionally the crosstalk with other immune cells provides an important source for 
NK cell stimulation. NK cells integrate an abundance of stimulatory and inhibitory signals that 
lead to the final decision: to kill or not to kill. Elucidation of the underlying mechanisms will 
greatly advance our knowledge in the fight against cancer and infectious diseases. 
Introduction 
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Fig. 2: NK cell regulation requires balance. NK cells engage inhibiting and activating ligands on the 
target cell surface and are further influenced by their surroundings. If the balance of activation and 
inhibition is disturbed, the NK cell can be activated to lyse its target ad secrete pro-inflammatory 
cytokines. 
  
I.2 Inhibitory NK cell receptors 
 The first inhibitory receptors of NK cells were described in mice (Karlhofer et al., 
1992) as C-type lectin like proteins. The Ly49 receptors comprise a small family of type II 
transmembrane-anchored glycoproteins with considerable allelic polymorphism (Mehta et al., 
2001) that recognize MHC I molecules. The inhibitory members of the Ly49 family signal via 
an immunoreceptor tyrosine-based inhibition motif (ITIM) in their cytoplasmic domains. But 
apart from inhibitory receptors this family also includes molecules with activating features. 
These activating receptors lack a cytoplasmic domain and instead pair with the ITAM 
containing adaptor molecule DAP12 through a charged amino acid in their transmembrane 
domain and therefore are able to transmit activating signals. 
 The Ly49 family does not exist in humans. Instead in a remarkable example of 
convergent evolution human NK cells express inhibitory type I transmembrane receptors of 
the immunoglobulin (Ig)-superfamily. These so called killer cell Ig-like receptors (KIR) are 
expressed by NK cells but also by γδTCR+ T-cells and memory/effector αβTCR+ T-cells 
(usually CD8+ T-cells and some CD4+ T-cells, but not thymocytes or naive T-cells) (Ferrini et 
al., 1994; Phillips et al., 1995). KIR receptors may contain two (KIR2D) or three (KIR3D) Ig-
Introduction 
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like domains. These receptors, just like receptors of the Ly49 family, can be equipped with 
different signaling domains: either an inhibitory ITIM in the cytoplasmic tail, or a charged 
amino acid in the transmembrane region to couple to adaptor molecules with activating 
potential. Due to these characteristics the receptors are denoted as long (L; KIR2DL or 
KIR3DL) or short (S; KIR2DS or KIR3DS). The KIR family consists of 15 genes and 2 
pseudogenes. Diversity within the KIR family can still be increased by differential splicing and 
allelic polymorphism (Selvakumar et al., 1997). Different KIRs recognize different human 
leukocyte antigen (HLA) -A, HLA-B and HLA-C molecules. An overview of the KIR receptors 
and their corresponding ligands is given in fig. 3. Many HLA-A and HLA-Bw6 allotypes 
apparently do not have a corresponding KIR, indicating that the KIR repertoire is not all-
inclusive for human class I allotypes (Lanier, 1998). Unlike T-cells NK cells bind to HLA 
molecules on the potential target cell surface regardless of the peptide presented. Although 
there is evidence that the peptide bound in the MHC peptide groove can affect KIR binding, 
the functional outcome of these observations is uncertain (Mandelboim et al., 1997).  
 
 
Fig. 3: Inhibitory NK cell receptors and their ligands.  
 
 In addition to these Ig-like receptors that recognize conventional MHC I molecules, 
the CD94/NKG2 family of C-type lectin like receptors is involved in the recognition of the 
unconventional MHC I molecule HLA-E. HLA-E presents leader-peptides derived from 
conventional MHC I molecules and thus indicates the overall presence of MHC I. The 
CD94/NKG2 family has already been identified in primitive organisms like teleostean fish and 
tunicates (Khalturin et al., 2003; Sato et al., 2003), which hints at an early system of 
self/nonself discrimination. In humans this family comprises CD94, NKG2A, -C, -E and –F. 
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Unlike the KIR family these receptors show only limited genetic polymorphism. CD94 is 
expressed as a disulfide-linked homodimer or as a disulfide-linked heterodimer with NKG2A 
or NKG2C. Interestingly, only NKG2A leads to inhibitory signals via an ITIM in its cytoplasmic 
domain. The CD94/NKG2C heterodimer signals in an activating fashion similar to the short 
KIR receptors. This finding might seem not very sensible for a start. But the inhibitory 
CD94/NKG2A heterodimer has a higher affinity for HLA-E molecules than the complex 
involving NKG2C (Vales-Gomez et al., 1999). Furthermore it has been suggested that 
proteins bound to the HLA-E complex can affect CD94/NKG2A affinity and therefore permit 
NK cells to be activated by the CD94/NKG2C complex in some cases (Michaelsson et al., 
2002). This concept of having several receptors for the same target molecule but with 
different affinities and signaling properties is again a good example for the tight balance of 
NK cell regulation. 
 Both receptor families, KIR and NKG2, can be phosphorylated at the tyrosine residue 
central to their ITIMs and recruit the SH2 domain containing phosphatases (SHP)-1 and 
SHP-2 upon engagement (Long et al., 2001). These phosphatases interfere with the 
recruitment of activating receptors into specialized membrane domains called lipid rafts and 
therefore abort the initial events of NK cell activation (Watzl et al., 2000).  
 Apart from the MHC I dependent NK cell inhibitory receptors there are also numerous 
receptors with inhibitory features that do not bind MHC I molecules. The homophilic receptor 
carcinoembryogenic antigen cellular adhesion molecule 1 (CEACAM1) has been shown to 
be upregulated in patients with TAP2 deficiency (Markel et al., 2004). Thus, it seems that 
expression of the ITIM containing receptor CEACAM1 can prevent autoaggression in the 
absence of MHC I molecules and therefore functions as an inhibitory NK cell receptor. 
Although NK cells without adequate MHC I binding receptors are rendered hyporesponsive, 
expression of CEACAM1 might provide a fail-safe mechanism. Another non-MHC I binding 
inhibitory receptor belongs to the family of sialic-acid-binding immunoglobulin-like lectins 
(SIGLECs). SIGLEC7 is the only SIGLEC family member expressed on NK cells. This 
receptor contains two ITIMs and is known to bind sialic acid residues (Ito et al., 2001). 
Crosslinking of SIGLEC7 on the NK cell surface leads to inhibition of target cell lysis (Nicoll 
et al., 2003). Although expression of compatible MHC I molecules still seems to be the main 
mechanism of NK cell inhibition, these additional inhibitory receptors provide important 
signals for the NK cell as well.  
  
I.3 Activating NK cell receptors 
 The group of NK cell activating receptors is much more heterogeneous than the 
inhibitory fraction. The receptors known to date cover several different families and use 
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distinct signaling pathways. Fig. 4 illustrates the established NK activating receptors except 
CD16 as this receptor does not recognize cellular ligands. 
  
 
Fig. 4: Overview of the known activating NK cell receptors and their ligands.  
 
Among the activating receptors CD16 takes a special place. This low affinity Fc-
receptor is responsible for a phenomenon called ‘antibody-dependent cellular cytotoxicity’ 
(ADCC). Upon encounter with an opsonized target CD16 can activate the NK cell to secrete 
cytokines and lyse the respective target cell. In fresh NK cells CD16 seems to be the only 
receptor to activate degranulation without co-engagement of several other receptors 
(Bryceson et al., 2006b). Interestingly it has been described that CD16 induces degranulation 
without prior polarization of granules. For specific polarization engagement of further 
activating receptors or adhesion molecules was necessary (Bryceson et al., 2006a). Upon 
activation of CD16, its adjacent signaling molecules FcεRI-γ or CD3ζ become 
phosphorylated within their ITAMs and transmit the signal further downstream through 
various molecules including ZAP70, phospholipase Cγ (PLCγ), phosphatidylinositol-3 kinase 
(PI3K) and mitogen activated protein (MAP) kinases.  
 Apart from CD16 and its unique role for NK cell biology, the squad of activating 
receptors includes NKp30, NKp44, NKp46, 2B4, NTB-A, CS1, NKp80, DNAM-1 and NKG2D 
as depicted in fig. 4 (Bottino et al., 2005). NKp30, NKp44 and NKp46 belong to the family of 
natural cytotoxicity receptors (NCR) and will be discussed in detail later on. 2B4, NTB-A and 
CS1 are members of the SLAM-related receptor (SRR)-family. These receptors are not 
confined to NK cells but are expressed on different immune cells such as T- and B-
lymphocytes, macrophages, monocytes and dendritic cells. SRR consist of two or four Ig-like 
domains in their extracellular part and are equipped with immunoreceptor tyrosine-based 
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switch motifs (ITSM). This motif can be used to bind either activatory or inhibitory adaptor 
proteins and therefore can lead to different signaling outcomes. Except 2B4, the SRR serve 
as their own ligands because they are homophilic. 2B4 binds to CD48, a 
glycosylphosphatidyl-inositol (GPI)-anchored member of the CD2 family. On most cell types 
these receptors seem to serve the purpose of fine-tuning the immune response (Bhat et al., 
2006). On NK cells however, these receptors can induce cytotoxicity and cytokine release. 
Nevertheless, SRR on NK cells can also enhance signals from other activating receptors and 
therefore fulfill a co-stimulatory function (Bryceson et al., 2006b). NKp80, just like NKG2D is 
a member of the C-type lectin like family which will be discussed further in chapter I.4. 
DNAM-1 is a receptor of the Ig-superfamily and recognizes the molecules CD112 (polio virus 
receptor, PVR) and CD155 (nectin-2). This receptor can activate NK cells but as for the SRR 
its role seems to be constricted to mainly co-stimulatory functions .  
 
I.4 The lectin like family of receptors 
 C-type lectin like family members on NK cells are diverse and most of them are not 
well studied yet. Genes for these receptors are found in the NK Gene complex (NKC) 
present on human chromosome 12p13. General features of this family include the formation 
of disulfide-linked homo- or heterodimers and a type II transmembrane orientation 
(Yokoyama and Plougastel, 2003). The lectin-like receptors encoded in the NKC can have 
either activating or inhibitory function and play an important role in regulation of NK cell 
activity. This gene complex also includes the previously mentioned genes for NKp80 and its 
ligand AICL, as well as the NKG2 family members and CD94. The NKp80 ligand, AICL, is 
expressed on monocytes, macrophages and granulocytes. Therefore, NKp80 likely is 
involved in the crosstalk of NK cells with myeloid cells and influences the initiation and 
maintenance of inflammatory responses (Welte et al., 2006). Other members of the NKC are 
NKRP1A, LLT1, and CD69. Interestingly in some cases the genes for the receptors and their 
ligands are found in close proximity as for NKp80 and AICL and for KLRP1A and Clr (Iizuka 
et al., 2003; Welte et al., 2006). As has already been described the receptor dimers of 
NKG2A/CD94 and NKG2C/CD94 bind to the same ligands, namely HLA-E molecules, but 
transmit opposing signals which are important for NK cell regulation. 
 Another receptor found in the NKC is NKG2D. It shows only minor homology to the 
remaining NKG2 family members. NKG2D is expressed as a homodimer and not as a 
heterodimer with CD94. It recognizes several cell surface glycoproteins that are structurally 
related to MHC I molecules. Among these are MICA, MICB and UL16 binding proteins 
(ULBP) 1-4. A common feature of these ligands is that they are upregulated on the surface of 
stressed or virally infected cells. On primary cells the MICA and MICB proteins can be 
upregulated after initiation of a DNA damage response through irradiation (Gasser et al., 
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2005). The MICA and MICB molecules can be found on various tumor cell lines where they 
are probably induced through heat shock proteins which become expressed upon malignant 
transformation (Groh et al., 1999). As tumors are flexible systems that adapt quickly to their 
surroundings they are able to escape this kind of surveillance. For many tumors the secretion 
of soluble MICA molecules has been reported. This leads to a downregulation of the NKG2D 
receptor from the NK cell surface and to anergy of the respective NK cell (Salih et al., 2003). 
Another important stimulus that leads to upregulation of NKG2D ligands on target cells is the 
infection with human cytomegalovirus (HCMV) (Guma et al., 2006). NKG2D does not have a 
cytosolic signaling domain but pairs with the adaptor molecule DAP10 through charged 
amino acids within its transmembrane domain. DAP10 then promotes the activating signal 
through activation of PI3K and binding of Grb2 and Vav1 (Wu et al., 1999). In mice, NKG2D 
can also pair with the adaptor protein DAP12, which is not possible in humans  (Lanier, 
1998). The activation of NKG2D leads to potent cytotoxic response and also to the 
production of cytokines. Though beneficial in most cases, NKG2D has also been implicated 
in autoimmune diseases. Patients with rheumatoid arthritis have been found to carry an 
unusual type of CD4+ T-cells in their inflamed joints that lacks CD28 but expresses NKG2D 
(Groh et al., 2003). In addition, NKG2D has also been linked to the onset of autoimmune 
diabetes in NOD mice (Ogasawara et al., 2004). For many members of the KIR and C-type 
lectin like family twin receptors have been described that bind the same ligand but transmit 
opposite signals. This has not yet been the case for NKG2D. Despite its importance for NK 
cell biology this receptor still retains its solitary position with no inhibitory counterpart 
described yet.  
 
I.5 The family of Natural Cytotoxicity Receptors (NCR) 
 Apart from NKG2D, the NCR constitute the main triggering receptors on NK cells. The 
family of NCR comprises three members, NKp30 (NCR3, CD337), NKp44 (NCR2, CD336) 
and NKp46 (NCR1, CD335) that have been described several years ago (Pende et al., 1999; 
Pessino et al., 1998; Vitale et al., 1998). All three receptors belong to the Ig-superfamily. 
Crosslinking of these receptors with antibodies induces a strong cytotoxic response and the 
secretion of cytokines. In contrast to the other triggering receptors mentioned previously, the 
expression of the NCR seems to be confined to NK cells. While other more widely expressed 
receptors like the SRR or DNAM-1 might function as a co-receptor, the NCR are able to 
provide potent activating stimuli to the NK cell. NKp30 and NKp46 are readily expressed on 
resting and activated NK cells, while NKp44 is only upregulated after stimulation with IL-2. In 
mouse only NKp46 has a functional homologue named Ncr1. Both NKp30 and NKp44 do not 
have homologues in mice. Therefore, in vivo research on these receptors is not possible. 
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 The extracellular domain of NKp46 is formed by two C2-type Ig-like domains. The 
cytoplasmic tail is very short and does not contain any known signaling motif. Instead, NKp46 
pairs with the ITAM containing CD3ζ or FcεRIγ adaptor proteins probably through charged 
amino acids in their transmembrane domain. Ligands for the NCR seem to be widely 
expressed on many tumor cell lines but also to a lesser extend on primary cells. The identity 
of the cellular NKp46 ligand on tumor cells was postulated to involve heparan sulfate 
structures (Bloushtain et al., 2004). Apart from this finding, NKp46 has been described to 
directly recognize viral gene products on the surface of infected cells. It can be directly 
triggered to lyse target cells by the presence of viral hemagglutinins, especially that of 
influenza virus and the sendai virus hemagglutinin-neuraminidase (Mandelboim et al., 2001). 
Influenza infection in NKp46 knockout mice results in lethal infection but only minor problems 
in tumor clearance (Gazit et al., 2006). Therefore NKp46 is at least in mice vitally important 
to combat influenza virus infections. As influenza virus is a very dangerous human pathogen 
this again emphasizes the role of NK cells as a first line of defense before the onset of the 
adaptive immune response. The recognition process of hemagglutinins is mediated by sialic 
acid linked to a sugar residue in the membrane proximal domain of NKp46. (Arnon et al., 
2004). Interestingly, the NKp46 mediated interaction is not only important for the clearance of 
virus infected cells but also for the activation of the adaptive immune response against 
influenza and other pathogens. Dendritic cells (DCs) infected with influenza virus have been 
shown to stimulate IFN-γ secretion of NK cells through engagement of NKp46 and NKG2D 
(Draghi et al., 2007). In addition to the NK-DC crosstalk, NKp46 activation has also been 
implicated in the lysis of monocytes infected with the intracellular bacterium Mycobacterium 
tuberculosis (Vankayalapati et al., 2002). Here it seems that this effect was mediated through 
increased expression of the filamentous protein vimentin on the surface of infected 
mononuclear phagocytes (Garg et al., 2006). 
 In a fashion similar to NKp46, NKp44 has been shown to be activated by influenza 
virus hemagglutinins (Arnon et al., 2001). However, its domain structure is quite different. In 
contrast to NKp46, NKp44 is equipped with a single V-type Ig-like domain in its extracellular 
sequence. Another difference to NKp46 is that NKp44 is expressed as a disulfide linked 
homodimer with charged surface grooves in each subunit (Cantoni et al., 2003). Although 
NKp44 shows an ITIM consensus sequence in its cytoplasmic domain, no signal transduction 
has been demonstrated to occur through this motif. In fact, this ITIM seems to be non-
functional and not able to recruit inhibitory signaling proteins (Campbell et al., 2004). Hence, 
the main signal transduction process upon NKp44 activation seems to be mediated through 
its pairing with the small ITAM containing adaptor molecule DAP12. This interaction probably 
is conferred through a lysine residue within the transmembrane domain of NKp44. Another 
similarity to the NKp46 receptor is that NKp44 seems to have a preference for binding to 
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heparan sulfate residues on tumor cells as well (Hershkovitz et al., 2007). Another interesting 
finding is that the ligand for NKp44 is upregulated on CD4+ T-cells upon infection with human 
immunodeficiency virus (HIV). This effect is mediated by a peptide found within the envelope 
protein gp41 of HIV (Vieillard et al., 2005). This leads to lysis of the respective cells by 
activated NK cells but what might even be more important this fact could also explain the 
phenomenon of reduced NCR expression and NK cell function in the blood of HIV-patients 
(De Maria et al., 2003).  
 The third member of this family is NKp30. This receptor has one V-type Ig-like domain 
in its extracellular part and pairs with the adaptor molecule CD3ζ through charged amino 
acids in its transmembrane domain just like NKp46. Crosslinking of NKp30 leads to 
cytotoxicity and cytokine secretion of NK cells. Again, heparan sulfate residues were 
postulated as NKp30 ligands on tumor cells but these results are vigorously debated 
(Bloushtain et al., 2004; Warren et al., 2005). It would seem, as all NCR have been shown to 
bind heparan sulfate residues that this might function merely as a rather unspecific co-ligand 
instead of a functional activating molecule.  In contrast to NKp44 and NKp46, NKp30 has not 
been linked to the binding of viral hemagglutinins. However, NKp30 has been implicated in 
the recognition of Trypanosoma brucei infected erythrocytes (Mavoungou et al., 2007). In this 
case it seems that a protein of T. brucei that is inserted into the erythrocyte membrane is 
able to activate NKp30 specifically. Another pathogen associated activation of NKp30 occurs 
during the lysis of filovirus infected DCs. This viral family comprises highly pathogenic strains 
like Ebola and Marburg virus. Early cytokine production is a key determinant for later survival 
which implicates that activation of the innate immune system is necessary. NKp30 is able to 
recognize virus like particles of the filovirus type and activate NK cells to produce cytokines 
(Fuller et al., 2007). Another striking feature of NKp30 is its involvement in the crosstalk 
between NK cells and DCs. NK cells are able to lyse immature DCs through engagement of 
NKp30 despite MHC I expression, but mature DCs are protected from lysis (Ferlazzo et al., 
2002). Additionally, NK cells that have been stimulated through NKp30 can produce tumor 
necrosis factor α (TNF-α) which then induces maturation of DCs (Vitale et al., 2005). DCs in 
return produce cytokines like IL-12 or IL-18 that can stimulate NK cells (Walzer et al., 2005). 
The mutual control and regulation of DCs and NK cells again is an interesting example how 
cells of the immune system communicate and work together in numerous ways. Especially 
NK cells and DCs through their communication among each other are crucial in bridging the 
innate and the adaptive immune response.  
 Signal transduction of the NCR shows similarities with signal transduction through the 
B- or T-cell receptor. All three receptors transmit their signal through ITAMs of the different 
adaptor molecules they engage. Upon phosphorylation of the ITAMs by the protein tyrosine 
kinases (PTKs) Lck and Fyn other PTKs like ZAP70 or Syk are recruited to transduce the 
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signal further downstream. Remarkably, activation of one NCR leads to additional signal 
transduction through the adaptor molecules associated with the remaining NCR (Augugliaro 
et al., 2003). That means, there is a highly productive crosstalk that involves the membrane 
proximal signaling molecules of the NCR but not those of others as CD16 or KIR2DS4. It 
seems that the NCR, though structurally different, act in concert as a functional coordinated 
complex on the NK cell surface. This complex might also involve the GPI-anchored protein 
CD59 that usually functions as a complement inhibitory protein. Though ubiquitously 
expressed, on NK cells CD59 is physically associated with NKp30 and NKp46 and can 
function in a co-stimulatory manner (Marcenaro et al., 2003).  
 Another hint as to the concerted action of the NCR is the concomitant regulation of 
their ligands through various pathogens. Ligands for all three NCRs are upregulated on cells 
infected with Herpes simplex virus. Here, the viral gene product ICP0 is sufficient to trigger 
the upregulation of all NCR ligands (Chisholm et al., 2007). The same phenomenon can be 
observed after infection of fibroblasts with vaccinia virus (Chisholm and Reyburn, 2006). For 
both observations it is rather clear that not a viral gene product is the respective ligand but 
that the endogenous cellular ligands are upregulated upon contact of the cellular machinery 
with the virus. This mechanism seems to constitute an important antiviral defense of the 
innate immunity. It is therefore crucial to elucidate the nature of the NCR ligands to be able to 
further explore this. 
 
I.6 A game of hide and seek - NK cells and cytomegalovirus 
The β-herpesvirus HCMV has for a long time been a commensal of the human 
population. About 90% of the population are carriers. Infection usually occurs at young age 
as a rather symptomless cold-like sickness. Most people are able to control the spread of the 
virus which then establishes a lifelong latent state without any symptoms. However, HCMV 
can be reactivated and cause serious illness in immunocompromised patients. This usually 
happens in elderly people, after organ transplantation or upon HIV induced AIDS. If acquired 
during pregnancy, HCMV can cause severe congenital disorders such as hearing loss, 
chorioretinitis and mental retardation (Pass, 2001). Due to a long time of co-evolution HCMV 
and its human host have achieved a delicate balance allowing the virus to replicate and 
spread without causing too much harm. The innate immune system and NK cells in particular 
play an important role in the maintenance of this balance.  
 HCMV has a large genome of about 230 kbp. A lot of the genes encoded are 
dedicated to the modification and control of the host cell machinery and immune escape. The 
complete replication cycle takes place in fibroblasts although monocytic cells are assumed 
as permanent reservoirs of latent virus. Gene expression during replication follows a tight 
schedule involving three cascades of immediate early, early and late genes. Much of the 
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data available today was obtained with the use of laboratory HCMV strains that have 
undergone genetic changes and deletions through long term in vitro culture. This might lead 
to biased results as in an in vivo situation the conditions for successful replication are rather 
different (Cerboni et al., 2000). However, dissection of the specific pathways involved in 
immune escape only became possible after the cloning of the genome of the laboratory 
strain AD169 as a bacterial artificial chromosome or bacmid (BAC) (Adler et al., 2003). This 
opened up the whole field of reverse genetics for manipulation of the HCMV genome.  
HCMV has evolved a whole battery of strategies to evade detection and attack by the 
host immune system. In turn of course the human immune system has adapted to these 
immune evasion strategies and is able to control this viral infection. HCMV expresses a 
remarkable repertoire of regulatory genes that interfere with host signaling pathways. They 
affect for example apoptosis, cytokine signaling or cell migration. A very important 
mechanism concerning the T- and NK cell mediated surveillance is the ability of HCMV to 
downmodulate MHC I and MHC II expression from the surface of the infected cell. This is a 
very effective way of escaping T-cell control because these cells are not activated through 
lack of MHC I but through the presentation of foreign peptides on MHC I molecules. The 
genes implicated in this process so far are US2, US3, US6 and US11. Although other viral 
gene products can bind MHC molecules as well, these are not necessarily involved in 
downmodulation. US3 is able to retain MHC I molecules within the endoplasmic reticulum 
(ER), while US2 and US11 dislocate MHC I from the ER into the cytoplasm where it is 
degraded. US6 impairs TAP-mediated peptide transport (Furman et al., 2002; Tortorella et 
al., 2000). Of course, as described in the chapter about inhibitory receptors, according to the 
‘missing self’ hypothesis, the lack of MHC I molecules on the target cell surface would lead to 
NK cell activation. However, HCMV has also evolved strategies to avoid the activation of NK 
cells.  
It seems that the non-classical MHC molecule HLA-E that is recognized by the 
inhibitory NK cell receptor CD94/NKG2A is not downmodulated from the surface of infected 
cells. HLA-E presents leader peptides derived from other processed HLA molecules and 
therefore is seen as a marker for overall MHC I expression. The HCMV protein UL40 
includes a peptide that is loaded onto HLA-E molecules if MHC I leader peptides are in short 
supply. This loading process occurs in a TAP-independent manner and increases HLA-E 
expression on the infected cell surface (Llano et al., 2003). Again, this mechanism can be 
counteracted by the existence of HLA-E specific cytotoxic T-cells. It has been reported that 
these cells can recognize the UL40 peptide bound to HLA-E and lyse the infected cell (Pietra 
et al., 2003). Another possibility would be the engagement of the activating receptor pair 
CD94/NKG2C by the combination of HLA-E/UL40, but this interaction has not been 
conclusively demonstrated yet. 
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As just discussed, NK cells do not only receive negative signals from a putative target 
cell but also activating stimuli. As a logical consequence HCMV might also have evolved 
means to avoid expression of activating NK cell ligands. It is of note that recently the HCMV 
gene product UL141 has been demonstrated to interfere with the expression of CD155, the 
ligand of the activating NK cell receptor DNAM-1. Interestingly, this HCMV protein is not 
found in the laboratory strains commonly used and has therefore not been implicated in 
HCMV immune evasion previousy (Tomasec et al., 2005). The interaction of other activating 
NK cell receptors and their ligands is affected by HCMV infection as well. Upon infection, the 
stress inducible NKG2D ligands are upregulated on the target cell surface. HCMV 
counteracts this alarm signal by expression of various proteins. Of the known NKG2D ligands 
the HCMV gene product UL16 is able to bind to MICB, ULBP1 and ULBP2 but not MICA or 
ULBP3 and prevent their presentation on the cell surface (Cosman et al., 2001). It has not 
been shown how this impacts on NK activity in an in vivo setting but it seems that this action 
can inhibit activation of NK cells at least in vitro (Dunn et al., 2003).  
The interaction of NKG2D and its ligands plays a particular important role in mice. 
Here, several viral proteins are engaged in the downmodulation of the mouse NKG2D 
ligands. Mutant viruses that do not express these proteins have severe problems during the 
replication process because of their increased susceptibility to NK cell recognition (Mocarski, 
2004). The viral protein m152 is not only able to inhibit the passage of MHC I molecules to 
the surface but also the structurally related mouse NKG2D ligand RAE-1. Additionally the 
m155 gene product is able to suppress presentation of H60. Some mice strains can control 
HCMV infection better than others. While BALB/c mice are usually highly susceptible to 
HCMV infection, the mouse strain C57BL/6 can easily clear the virus. This has been ascribed 
to the presence of the receptor Ly49H. In its presence the NK cell response against MCMV is 
enhanced enormously. The ligand for this activating mouse NK cell receptor is the viral m157 
gene product. This protein shows structural similarities to MHC molecules and engagement 
by Ly49H leads to strong activation of the NK cell response. The Ly49 family does not exist 
in humans. Instead NK cells dispose of an array of MHC binding KIR receptors. Viral ligands 
for these receptors have not been described yet, but they might emerge with further 
research. 
 The NCR are very important receptors for NK cell activation. Their yet unknown 
ligands have been shown to be upregulated during various viral infections like Herpes 
simplex or vaccinia virus. HCMV is so far the only virus that has been demonstrated to 
dispose of a defense mechanism against recognition by NK cells through NKp30. The 
tegument protein pp65 of HCMV seems to have the ability to bind to NKp30 and dislocate the 
signaling CD3ζ chain in a way that makes signal transduction impossible and therefore 
interferes with NK cell activation (Arnon et al., 2005). Although pp65 is not a secreted protein 
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and high concentrations in the medium are required to mediate this effect it is nevertheless a 
functional but inhibitory NKp30 ligand. The overall effect of HCMV on the expression of the 
NCR ligands has not been examined yet. For the residual NCR NKp44 and NKp46 no viral 
inhibitory proteins are known. It is possible that the increased expression of their ligands 
might compensate for the inhibition of NKp30.   
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Aim of the thesis 
 The general aim of this thesis was to elucidate new molecules and mechanisms 
involved in the recognition of putative target cells by NK cells. 
 NK cells express a multitude of receptors with either activating or inhibiting function. 
Many of these are engaged upon contact with a putative target cell and transmit a precise 
picture of the target cell status. The final outcome of this signal integration process is the 
decision whether the NK cell is to be activated to lyse the target cell or not. A fine balance of 
these signals is required to enable the defense against pathogens and cancer and at the 
same time avoid autoimmune reactions. Characterization of the molecules that are involved 
in creating and maintaining this balance will not only advance our knowledge in the field of 
innate immunity, it might lead to advances in cancer research as well. 
 The NKG2 family contains inhibiting as well as activating receptors. Interestingly 
some of these receptors form pairs that have the same ligand but different signaling 
capacities. NKG2D plays a very important role for NK cell biology as an activating receptor. 
For NKG2D no inhibitory counterpart has been described to date. One aim of this thesis was 
to examine whether NKG2D would have an inhibitory counterpart and the characterization of 
the putative molecule. 
The family of the activating natural cytotoxicity receptors including the members NKp30, 
NKp44 and NKp46 is thought to play an important role in tumor rejection and viral defense. 
Although the ligands for these molecules are elusive to date they can be detected on the cell 
surface with functional assays and with the help of soluble fusion proteins. These proteins 
contain the extracellular domain of the respective receptor and a tag that can be detected 
with an antibody. As human cytomegalovirus is a highly specialized pathogen that has 
evolved numerous ways of immune escape, concerning NK cells in particular, it is an 
interesting questions whether the NCR play a role in the defense against this virus. Therefore 
the modulation of NCR ligands by cytomegalovirus was to be further analyzed. For further 
research on the NCR and their impact on NK cell activity it is crucial to elucidate the nature of 
the unknown NCR ligands. Therefore yet another aim of this thesis is to finally obtain 
answers to this question of the identity of the NKp30 ligand. 
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M. Material and Methods 
 
M.1 Material 
 
M.1.1 Antibodies 
mouse monoclonal antibodies 
name antigen source, reference 
MOPC21 (IgG1κ) unknown Sigma Taufkirchen, Germany 
mouse IgG2aκ unknown BD Pharmingen, Heidelberg, 
Germany 
anti-ILZ isoleucin-zipper-motif (Stark et al., 2005) 
anti-CLEC12B (clone 16) CLEC12B (Hoffmann et al., 2007a) 
anti-his (AD1.1.10) histidine-tag Serotec, Oxford, UK 
4G10 (biotinylated) phosphotyrosine Upstate, Charlottesville, VA, 
USA 
anti-SHP-1 SHP-1 (aa 492-597) BD transduction labs, 
Heidelberg, Germany 
anti-SHP-2 SHP-2 (aa1-177) BD transduction labs 
anti-NKp30 (p30-15) NKp30 (CD337) 
extracellular domain 
(Hoffmann et al., 2007b) 
10E4 (ascites fluid) heparan sulfate 
proteoglycan 
United States Biological 
Swampscott, Massachusetts, 
USA 
anti-NKG2D NKG2D R&D systems 
 
rabbit polyclonal antibodies 
name antigen source, reference 
anti-actin actin C-terminal peptide Sigma-Aldrich 
 
secondary antibodies 
name antigen source, reference 
goat anti-human IgG 
(biotinylated) 
Fc portion of human IgG Jackson ImmunoResearch, 
Laboratories, West Grove, PA, 
USA 
goat anti-mouse IgG , PE mouse IgG Jackson ImmunoResearch 
goat anti-mouse IgG, HRPO mouse IgG Jackson ImmunoResearch 
goat anti-mouse IgG, TRITC mouse IgG Jackson ImmunoResearch 
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M.1.2 Bacteria 
strain use source 
E.coli TOP10 one shot amplification of plasmids Invitrogen 
 
 
M.1.3 Buffers, Chemicals and Reagents 
 
M.1.3.1 Buffers 
 
Lysis buffer (eukaryotic cells)   150 mmol/l  NaCl 
20 mmol/l  Tris-HCl, pH = 7.4 
10 % (v/v)  Glycerol 
0.5 % (v/v)  Triton X-100 
2 mmol/l  EDTA 
10 mmol/l  NaF 
1 mmol/l  PMSF 
(for studies on protein phosphorylation) 
1 mmol/l  Na-orthovanadate 
 
DNA-sample buffer (6 x)    0.25 % (w/v)  Bromphenol Blue 
0.25 % (w/v)  Xylene Cyanol FF 
30 % (v/v)  Glycerol in H2O 
 
MOPS buffer (20 x)     Invitrogen, Carlsbad, CA, USA 
 
PBS       137 mmol/l  NaCl 
8.1 mmol/l  Na2HPO4 
2.7 mmol/l KCl 
1.5 mmol/l  KH2PO4 
pH = 7.4 
 
PBST       1 x PBS 
0.05 % (v/v)  Tween 20 
 
PBST/NaCl      1 x PBS 
0.05 % (v/v)  Tween 20 
0.5 mol/l  NaCl 
 
PBS/pervanadate    1 x PBS 
10 mmol/l  H2O2 
200 µmol/l  Na-orthovanadate 
 
Reducing sample buffer (5 x)   10 % (w/v) SDS 
50 % (v/v)  Glycerol 
25 % (v/v)  2-Mercaptoethanol 
0.1 % (w/v)  Bromphenol Blue 
0.3125 mmol/l TRIS-HCl, pH = 6.8 
 
TAE (10 x)      Invitrogen, Carlsbad, CA, USA 
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Western blot transfer buffer    24 mmol/l  Tris base 
129 mmol/l  Glycin 
20 % (v/v)  MeOH 
 
HBS (2x)      13 g/l (w/v)  HEPES 
16 g/l (w/v)  NaCl 
3 mmo/l  Na2HPO4 
pH = 7.0 
 
ILZ wash buffer    50 mM  NaH2PO4 
      300 mM NaCl 
20 mM  Imidazole  
0,05% (v/v)  Tween 20 
pH 8.0 
 
ILZ elution buffer    50 mM  NaH2PO4 
      300 mM NaCl 
      250 mM Imidazole 
      0.05% (v/v) Tween 20 
      pH 8.0 
 
IgG elution buffer    50 mM  citric acid 
      pH 3.0 
 
antibody wash buffer 1   3 M  NaCl 
      50 mM  Na-borate 
 
antibody wash buffer 2   3 M  NaCl 
      10 mM  Na-borate 
 
antibody elution buffer   100 mM glycine  
      pH 3.0 
 
 
M.1.3.2 Chemicals 
 
 Most chemicals were purchased from Roth (Karlsruhe, Germany), Sigma-Aldrich 
(Seelze, Germany), Merck (Darmstadt, Germany). 
 
M.1.3.3 Reagents 
 
Agarose     Invitrogen, Carlsbad, CA, USA 
Ampicillin     Roth, Karlsruhe, Germany 
BSA      Serva, Heidelberg, Germany 
Chondroitin sulfate    Sigma-Aldrich 
Chromium-51     Hartmann Analytik, Braunschweig, Germany 
DNA ladder (100 bp and 1 kb)  Invitrogen, Carlsbad, CA, USA 
Heparan sulfate    Sigma-Aldrich  
Heparin     Sigma-Aldrich 
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Heparinase III     Sigma-Aldrich 
Hyaluronidase    Sigma-Aldrich  
Interleukin-2 (IL-2)    NIH cytokine repository 
LB broth     Invitrogen 
Lipofectamin 2000    Invitrogen 
Lipopolysaccharide (LPS)   Sigma-Aldrich 
Milk Powder     Töpfer, Dietmannsried, Germany 
Ni-NTA Agarose     Qiagen, Hilden, Germany 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich  
Precision Plus Protein Standard  Biorad, Hercules, CA, USA 
Protein A Agarose    Sigma-Aldrich 
Protein G Agarose    Invitrogen 
Streptavidin HRPO    Jackson ImmunoResearch 
Streptavidin PE    Jackson ImmunoResearch 
TrypLE Express    Invitrogen 
X-ray films     Perbio/Pierce, Rockford, IL,USA 
 
M.1.4 Cells 
 All media were purchased from Invitrogen; Fetal calf serum (FCS), non-essential 
amino acids (NEAA) and sodium pyruvate were from Invitrogen; human serum was from 
PromoCell (Heidelberg, Germany) and horse serum from Biochrom (Berlin, Germany). X-
vivo10 medium was purchased from BioWhittaker (Verviers, Belgium). 
If not indicated otherwise all cell media were supplemented with 10% (v/v) FCS and 1% 
Penicillin/Streptomycin (Invitrogen). 
 
cell name origin culture medium 
primary human NK cell 
populations, NKpop 
isolated from buffy coats IMDM, 10% human serum, 1% 
NEAA, 1% sodium pyruvate, 
100 U/ml IL-2 
primary human 
macrophages, MΦ 
generated from monocytes 
from buffy coats 
X-vivo10, 2% autologous 
human serum 
human foreskin fibroblasts, 
HFF 
kind gift of Hygiene 
Institute, Heidelberg 
DMEM, 10µg/ml ciprofloxacine 
(Bayer) 
NKL (Robertson et al., 1996) RPMI, 100 U/ml IL-2 
NK92C1 (Gong et al., 1994) 
(Tam et al., 1999) 
Alpha medium, 12,5% FCS, 
12,5% horse serum, 50 µM β-
mercaptoethanol 
Hek-293T human embryonic kindney 
cells 
DMEM 
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Phoenix ampho Hek-293T derived virus 
packaging cell line 
DMEM 
721.221 EBV-transformed B-cell 
line, human 
IMDM 
CHO chinese hamster ovary 
cells 
RPMI, 50 µM β-
mercaptoethanol 
CHO pgsA-745 CHO deficient in protein 
glycosylation (Esko, 1991) 
RPMI, 50 µM β-
mercaptoethanol 
EM-3 EBV-transformed B-cell 
line, human 
RPMI 
Ba/F3 mouse pre-B cell line RPMI, 50 µM β-
mercaptoethanol 
Ag8 myeloma cells used for 
hybridoma generation 
RPMI, 50 µM β-
mercaptoethanol 
P815 Fc-receptor positive mouse 
mastocytoma line 
IMDM 
U937 human histiocytic 
lymphoma cell line 
(Sundstrom and Nilsson, 
1976) 
RPMI 
 
M.1.5 Virus strains 
 
Virus strains were a kind gift of Michael Winkler, University Kiel. 
name description 
AD169 laboratory hCMV-strain 
pHB5 bacmid of AD169, missing US2-US6 
WaBAC1 pHB5, missing TRL1-UL20 
WaBAC2 pHB5, missing IRL14-US1 
WaBAC3 pHB5, missing US7-US25 
 
M.1.6 Constructs 
 
name comment 
pBABE CLEC12B expression construct for CLEC12B, with his-tag 
pRK5 SHP-1 expression construct for SHP-1 
pRK5 SHP-2 expression construct for SHP-2 
pZipH CS1 CS1-ILZ fusion protein with his-tag 
pZipH NKp30 NKp30-ILZ fusion protein with his-tag 
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pMEG NKp30 NKp30-IgG fusion protein 
pMEG CD99 CD99-IgG fusin protein 
human 50K lentiviral siRNA 
library 
#SI206A-1 System Biosciences, Mountain View, 
CA  
 
M.1.7 Enzymes 
 
name use source 
restriction endonucleases DNA digest New England Biolabs, 
Frankfurt , Germany 
T4 DNA ligase DNA ligation New England Biolabs 
AMV reverse transcriptase RT-PCR First strand cDNA synthesis kit, 
Roche Diagnostics, 
Indianapolis, IN 
Fast Start Taq DNA 
Polymerase 
PCR New England Biolabs 
Titanium Taq DNA 
Polymerase 
PCR BD clontech, Mountain View, 
CA 
M-MLV reverse transcriptase RT-PCR Invitrogen 
T4 exonuclease double strand DNA digest New England Biolabs 
 
M.1.8 Oligonucleotides 
 
name sequence (5’ – 3’) 
cDNA synthesis TGCATGTCGCTATGTGTTCTGGGA 
siRNA fw AATGTCTTTGGATTTGGGAATCTTA 
siRNA rev AAAAAGGGTGGACTGGGATGAGTA 
siRNA nested fw bio CTTCCTGTCAGA (5’ biotinylated) 
siRNA nested rev ATAGAAAGAATGCTTATGGACGCTA 
CLEC12B fw CCGCTCGAGCAGATATCTAATGACATTAACTCAG 
CLEC12B rev GCCGCGGCCGCTTAATCCAAATCCTCAGTCTTCAG 
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M.2 Methods 
 
M.2.1  Molecular Biology 
 
M.2.1.1 Agarose gel electrophoresis 
 The DNA was mixed with 6x loading buffer and loaded onto the gel. According to 
DNA fragment size 1 % or 2 % (w/v) agarose gels were cast containing 0.001 ‰ 
ethidiumbromide. The correct size of the DNA fragment was controlled using a DNA ladder. 
 
M.2.1.2 DNA digest 
 Between 1 and 2 µg of DNA were incubated with 2  U of the respective restriction 
endonuclease for at least 1 h at 37°C. Conditions of the reaction were set according to the 
manufacturer’s instructions. The resulting DNA fragments were separated by agarose gel 
electrophoresis.  
 
M.2.1.3 DNA sequencing 
 Sequencing reactions were set up in a 20 µl volume with the ABI Big Dye sequencing 
mix v1.1 according to manufacturer’s instructions. After the sequencing reaction the DNA 
was precipitated from the samples with ethanol. Pellets were solubilised in water and 
analysed on an ABI Prism 310 Genetic Analyzer. 
 
M.2.1.4 Isolation of DNA fragments from agarose gels 
 After excision from the gel DNA fragments were extracted using the Qiagen gel 
extraction kit according to the manufacturer’s instructions. 
 
M.2.1.5 Isolation of plasmid DNA 
 Bacteria were grown in LB medium at 37°C over night with shaking. Cells were 
pelleted at 6200xg for 10 min. DNA was prepared using the Qiagen Mini, Midi or MaxiPrep 
DNA isolation kits according to the manufacturer’s instructions.  
 
M.2.1.6 Isolation of total RNA from eukaryotic cells 
 Routinely 1x107 cells were lysed and total RNA was extracted using the Qiagen 
RNeasy kit according to manufacturer’s instructions. 
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M.2.1.7 Ligation of DNA 
 The insert and vector DNA were mixed at a molar ratio of approximately 3:1 in 1x 
ligation buffer in a 10 µl volume. The mixture was incubated with 2 U T4 DNA ligase for 1 h 
at room temperature and used to transform competent bacteria. 
 
M.2.1.8 Polymerase chain reaction (PCR) 
 PCR was performed in a 50 µl volume containing 5 µl 10x Thermopol buffer, 0.2 mM 
of each dNTP, 0.4 µM forward and reverse primer, 5 U Taq-polymerase and up to  
5 µl template DNA or cDNA. Cycles were set according to the respective need, including 
denaturing at 94°C, annealing and elongation steps at 72°C. For amplification of siRNA 
sequences the suggested protocol of System Biosciences was followed including the use of 
Titanium Taq polymerase and elongation steps at 68°C.  
 
M.2.1.9 Reverse transcription (RT) 
 Usually reverse transcription of total RNA was performed using the First Strand cDNA 
Synthesis kit from Roche. For amplification of siRNA transcripts total RNA was prepared and 
reverse transcribed according to instructions given in the manual of the siRNA library. Briefly, 
total RNA was prepared and reverse transcribed using the cDNA synthesis primer included 
in the kit and M-MLV reverse transcriptase in the presence of DTT. 
 
M.2.1.10 Transformation of bacteria 
 Top10 bacteria were transformed according to the manufacturer’s instructions. 
Bacteria were grown on LB-agar plates at 37°C for at least 12 h and selected with the 
appropriate antibiotic.  
 
 
M.2.2  Cell Biology 
 
M.2.2.1 Cell culture 
 All cells were grown at 37°C and 5 % CO2 under sterile conditions. Cells were split on 
a regular basis every two to three days. Cell culture flasks were exchanged every week. 
Cells  were frozen in FCS containing 10 % DMSO at -75°C and stored in liquid nitrogen. Cell 
lines were thawed on a regular basis. FCS, horse serum and human serum were heat 
inactivated by incubation at 56°C for 30 min prior to use. 
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M.2.2.2 Cell cycle arrest 
 Cells were incubated over night with 0.1 µM colchicine or 100 ng/ml nocodazole to 
arrest the mitotic spindle. As a control cells were treated with DMSO or with 10 µM colchicine 
for 1 h. Cell cycle arrest was confirmed with PI staining of DNA content and flow cytometric 
analysis. 
 
M.2.2.3 Cell isolation 
Natural killer cell isolation 
 Peripheral blood mononuclear lymphocytes (PBMCs) were isolated from buffy coats 
via density gradient centrifugation using Ficoll reagent (PAA, Pasching, Germany). NK cells 
were isolated from the resulting lymphocyte population using the NK cell negative isolation kit 
from Dynal Biotech (Oslo, Norway). NK cells were only used when more than 90 % CD3- and 
CD56+. NK cells were cocultured with irradiated feeder cellsand activated with 2 µg/ml  
PHA-P and 100 IU/ml IL-2. 
Monocyte isolation and macrophage generation 
 Monocytes were isolated from PBMCs using the monocyte negative isolation kit from 
Dynal biotech. The resulting populations were at least 90 % CD14+. Monocytes were seeded 
into 175 cm2 tissue culture flasks and differentiated into macrophages through plastic 
adhesion for 10 days.  
Depletion of EM-3 cells 
 EM-3 cells were stained with NKp30-IgG fusion protein and biotinylated goat anti-
human secondary antibody. Then NKp30L positive cells were depleted using anti-biotin 
microbeads (Miltenyi, Bergisch Gladbach, Germany) using the QuadroMACS magnet 
system. Additionally, cells were sorted on a BD FACSvantage cell sorter.  
 
M.2.2.4 Cell lysis 
 If necessary, protein phosphorylation was induced using the phosphatase inhibitor 
pervanadate prior to lysis. For this purpose, 10x106 cells were stimulated with a 
PBS/pervanadate solution for 10 min at 37°C. After centrifugation, pelleted cells were 
resuspended in 0.5 % Triton X-100 lysis buffer supplemented with 1 mmol/l PMSF and if 
necessary 1 mmol/l Na-orthovanadate and incubated on ice for 20 min. Postnuclear 
supernantant was collected by centrifugation for 10 min at 16000 x g and 4°C. 
 
M.2.2.5 Chromium release assay 
 0.5x106 target cells were labeled in 100 µl assay medium (IMDM with 10 % FCS and 
1 % penicillin/streptomycin) with 100 µCi (3.7 MBq) of 51Cr for 1 h at 37°C. Cells were 
washed twice and resuspended at 5x104 cells/ml in assay medium. Effector cells were 
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resuspended in assay medium and if necessary preincubated with blocking antibodies (10 
µg/ml final concentration) for 15 min at 37°C. After preincubation effector cells were mixed at 
different effector to target (E:T) ratios with 5000 labelled target cells/well in a 96-well V-
bottom plate. Maximum release was determined by incubation of target cells in 1 % Triton X-
100 solution. For spontaneous release, targets were incubated without effectors in assay 
medium alone. All samples were done in triplicates. Plates were incubated for 4 h at 37°C. 
Supernatant was harvested and 51Cr-release was measured in a γ-counter. Percent specific 
release was calculated as ([experimental release – spontaneous release] / [maximum 
release – spontaneous release]) x 100. The ratio between maximum and spontaneous 
release was at least 3 in all experiments. For redirected lysis assay the Fc-receptor positive 
cell line P815 was used as target. Effector cells were preincubated with antibodies (0.5 µg/ml 
final concentration) against NK cell receptors. 
 
M.2.2.6 Flow cytometry 
Staining with antibodies 
 Extracellular surface staining was performed in 96-well V-bottom plates. About 1x105 
cells were resuspended in 50 µl fluorescence-activated cell sorting (FACS)-buffer (PBS / 2% 
FCS) containing 10 µg/ml of the respective primary antibody. After 20 min incubation on ice 
cells were washed with 150 µl FACS-buffer, centrifuged and resuspended in 50 µl FACS-
buffer with the appropriate secondary antibody (dilution 1:200). After another incubation on 
ice for 20 min, cells were washed again and resuspended in FACS-buffer containing 2% 
formaldehyde and analysed using a BD FACScan or a BD FACScalibur. Results were 
evaluated with the FlowJo sofware available from TreeStar, Ashland, OR.  
Propidium iodide (PI) staining 
 Cells (2x105) were washed with stain buffer (PBS / 0.5% FCS) in a FACS-tube. After 
centrifugation cells were resuspended in 50 µl ice cold stain buffer. Then 150 µl cold ethanol 
were added slowly while vortexing cells. Afterwards, cells were stored at 
 -20°C for at least 24 h. After another three wash steps, the supernatant was carefully 
removed and 300 µl of PI staining solution were added (20 µg/ml PI, 100 µg/ml RNase, 0.1% 
TX-100). After incubation for 30 min at room temperature cells were analysed via flow 
cytometry. 
Fusion protein staining 
 About 1x105 cells were resuspended in FACS-buffer, containing either 1 µg/ml 
isoleucin-zipper (ILZ)-fusion protein or 10 µg/ml IgG-fusion protein and incubated on ice for 
20 min. Then, cells were washed with 150 µl FACS-buffer and resuspended in 50 µl 
secondary antibody, either 5 µg/ml of mouse anti-ILZ or 10 µg/ml of goat anti-human IgG 
(biotinylated). After 20 min incubation on ice cells were washed again and resuspended in 
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fluorophore conjugated third reagent solution, either goat anti-mouse antibody (PE-
conjugated) or streptavidin (PE-conjugated). After a last incubation on ice, cells were 
washed, resuspended in 100 µl of FACS-buffer with 2% formaldehyde and analysed. 
 
M.2.2.7 Immunofluorescence 
 HFF cells were seeded on 12mm diameter round coverslips in 12-well plates at a 
density of 70000 cells per well. After CMV infection cells were washed once with  
PBS / 2mM MgCl2 and fixed for 7 min in 3% formaldehyde, 2% saccharose in PBS at room 
temperature. Coverslips were washed in PBS three times and permeabilised with PBS, 0.5% 
TX-100 for 10 min at 4°C. After another three wash steps, cells were incubated with 30 µl per 
coverslip of 5 µg/ml ILZ-fusion protein in PBS for 30 min on parafilm. As secondary antibody 
mouse anti-ILZ was used at a concentration of 10 µg/ml and as detection antibody goat anti-
mouse (TRITC-conjugated) in a 1:300 dilution. Coverslips were washed, dehydrated for 30 
sec in ethanol, dried and mounted onto object slides using fluoromount G (Southern 
Biotech). 
 
M.2.2.8 Inhibition of CMV replication 
Inhibition of immediate early / early phase 
 HFF cells were seeded into 6-well plates at a density of 2.5x105 cells per well. The 
next day 3 h prior to and after infection, cycloheximide was added at a concentration of 50 
µg/ml. Afterwards, cells were washed and incubated without inhibitor for 3 h. Then 
actinomycin D was added to a concentration of 20 µg/ml, cells were further cultivated for 14 
h and then harvested and analysed. 
Inhibition of late phase 
 For inhibition of the late phase of the viral life cycle, HFFs were seeded, cultivated 
and infected in the presence of 100 µg/ml phosphonoformate. 
UV-inactivation 
 Cell supernatant containing HCMV particles was plated in 3.5 cm plastic dishes at a 
layer thickness of 2-3 mm and irradiated for 20 min in a UV Stratalinker 1800 (Stratagene). 
After irradiation no infectious virus was detectable upon HFF infection. 
 
M.2.2.9 Production of CMV particles 
 To produce particles of the laboratory strain AD169 and its derivatives, human 
foreskin fibroblasts (HFFs) were seeded in 175 cm2 tissue culture flasks and infected with the 
respective strain. After 1-2 weeks the supernatant was harvested and cleared by 
centrifugation. Virus titer was determined in an in vitro plaque assay detecting production of 
viral proteins.  
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Wild type CMV is not found in the supernatant but spreads in a cell associated manner. 
Therefore, HFFs were seeded into 175 cm2 tissue culture flasks and already infected HFF 
were added. The state of infection could be monitored through the appearance of cytopathic 
effects in the cell layer. When the culture was thouroughly infected, cells were harvested and 
used in experiments. If not stated otherwise, HFF were infected at a multiplicity of infection of 
1 to 1.5. 
 
M.2.2.10 Transfection of eucaryotic cells 
Retroviral gene transfer 
 Retroviral gene transfer was done using the packaging cell line Phoenix ampho. At 
day one Phoenix cells were plated in a 25 cm2 tissue culture flask at a density of 2x106 cells 
in 4 ml medium and grown for 24h. Cells were transfected with the pBABE vector encoding 
the gene that was to be transduced using Lipofectamin 2000 according to manufacturer’s 
instructions. To increase transduction effiency an expression plasmid for the viral envelope 
protein VSV-G was added to the transfection mix. Twelve hours post transfection the 
medium was exchanged with the medium of the cells that were to be transduced and 
Phoenix cells were grown for an additional 24 h. Supernatant was harvested and cleared by 
centrifugation. For transduction, 0.5x106 cells were resuspended in the virus containing 
supernatant, supplemented with 5 µg/ml polybrene and if necessary IL-2 and infected by 
centrifugation for 1.5 h at 1000xg and 30°C. Spinfection was done in 12-well plates and cells 
were afterwards grown over night. The medium was exchanged the next day by pelleting 
cells and resupending them in fresh medium. Cells were plated on a new 12 well plate. After 
culturing infected cells for one day, puromycin was added at a concentration of 0.5 µg/ml to 
select for transfected cells. Transfected cells were expanded and if necessary further 
enriched by FACS. 
Calcium phosphate transfection 
 Hek-293T cells were plated in a 6-well plate at a density of 0.5x106 cells per well in  
2 ml medium and grown for 24h. Cells were then transfected by calcium posphate with 3 to 
10 µg DNA. For this purpose, 438 µl of sterile water were mixed with 61 µl of a 2 mol/l 
calcium chloride solution and DNA. 500 µl 2x HBS was added and mixed by bubbling 
vigorously. The mixture was then applied dropwise to the Hek-293T cells. After 12 h medium 
was exchanged. After an additional 24h cells were harvested, pelleted by centrifugation and 
lysed. 
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M.2.3  Protein-biochemistry 
 
M.2.3.1 Coomassie staining 
 Gels were washed three times for 5 min in deionized water, incubated for 1h with 
SimplyBlue Safe stain (Invitrogen, Carlsbad, CA) on a shaking incubator, washed again and 
dried. 
 
M.2.3.2 Generation of mouse monoclonal antibodies 
 For the generation of mouse monoclonal antibodies 10 week old female BALBc mice 
were immunized intraperitoneally with 5x106 Ba/F3 cells transfected with CLEC12B. 
Injections were repeated after day 21, 35 and 49. On day 63 mice were boosted with 50 µg 
of purified CLEC12B-IgG fusion protein in PBS and sacrificed three days later. The spleen 
was removed and spleen cells were isolated, washed three times in PBS and mixed with 
4x107 washed Ag8 cells. The cell mixture was pelleted by centrifugation at 1500 rpm for 5 
min, the supernatant was aspirated and cells were incubated at 37°C (waterbath, shaking) 
for 1 min. Afterwards 1 ml pre-warmed PEG 1500 was slowly applied to the cells within 1 min 
(waterbath, shaking) and the cells were incubated for an additional 1 min on 37°C 
(waterbath, shaking). Afterwards 10 ml pre-warmed PBS was applied dropwise to the cells 
within 5 min (waterbath, shaking). 50 ml HAT medium was added and cells were plated on 
five 96 well flat-bottom plates (100 µl/well). After one week the cells were fed with HAT 
medium (100 µl/well). After an additional week the supernatant was screened for secreted 
antibodies by ELISA with CLEC12B-IgG fusion proteins, positive clones were expanded and 
subcloned until a monoclonal hybridoma could be selected. The monoclonal antibody was 
purified from the supernant of the hybridoma cells on protein A agarose columns under high 
salt conditions. The culture supernatant was adjusted to 3.3 mol/l NaCl and 1/10 volume of a 
1.0 mol/l sodium borate solution (pH  8.9) was added. The mixture was then passed through 
a protein A agarose column. The beads were first washed with a buffer containing 3.0 mol/l 
NaCl, 50 mmol/l Na-borate, pH 8.9, followed by a wash with a buffer containing 3.0 mol/l 
NaCl, 10 mmol/l Na-borate, pH 8.9. The antibody was eluted using 100 mmol/l Glycine, pH 
3.0. The antibody was dialysed against PBS and the concentration was adjusted to 1 mg/ml. 
Antibodies were frozen at –20°C and working aliquots were stored at –20°C in 50 % glycerol. 
 
M.2.3.3 Immunoprecipitation 
 Lysate was pre-cleared and incubated for 1 h at 4°C with 2 µg of control IgG1 
antibody, followed by 2 µg specific antibody, both coupled to 20 µl of a 50 % slurry of 
recombinant protein G agarose in PBS. Samples were washed 3 times in ice-cold lysis 
buffer, beads were dried and stored at –20°C until samples were analyzed by SDS-PAGE/ 
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Western blot. 
 
M.2.3.4 Production of fusion proteins 
 ILZ fusion proteins were produced as described elsewhere (Watzl, 2006). IgG-fusion 
proteins were produced and purified as follows: Hek-293T cells were seeded into 5 175 cm2 
tissue culture flasks and transfected with 25 µg per flask of expression plasmid using the 
calcium phosphate method the next day. After 12-16 h the medium was exchanged and then 
harvested 2 and 5 days later and cleared by centrifugation. After filtration through a 0.22 µm 
sterile filter to remove small particles the supernatant was passed over a protein A column. 
Bound IgG-fusion protein was eluted with 50 mM citric acid pH 3.0. Fractions were 
neutralized with 1 M Tris pH 8.0. After dialysis against PBS the protein solution was 
concentrated using Vivaspin 6 columns (Vivascience, Stonehouse, UK) with a molecular 
weight cutoff of 10000 dalton. Fusion proteins were analysed for purity on coomassie stained 
SDS-gels.  
 
M.2.3.5 SDS-Polyacrylamid gel-electrophoresis (SDS/PAGE) 
 After adding 2.5x or 5x reducing sample buffer, samples were boiled for 5 min at 
95°C, centrifuged for 1 min and separated on NuPage gels (Invitrogen, Carlsbad, CA) using 
1 x MOPS buffer at 150 V for 1h 15 min. 
 
M.2.3.6 Western Blot 
 After SDS/PAGE proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore, Corporation, Bredford, MA) for 1.5 h at 200 mA in Western blot 
transfer-buffer. PVDF membranes were activated with methanol and washed with transfer-
buffer prior to use. After Western blotting, membranes were blocked with either 5 % BSA or  
5 % skimmed milk in PBST for 1 h at room temperature and incubated with the primary 
antibody over night at 4°C. The membrane was washed three times with PBST/NaCl and 
incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at 
room temperature. Secondary antibodies were diluted 1:20000 in 2.5 % skimmed milk in 
PBST. After incubation with the secondary antibody, the membrane was washed three times 
for 10 min with PBST and developed using either Super Signal West Pico or Dura (Pierce, 
Rockford, IL). 
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R. Results 
 
R.1 Characterization of CLEC12B 
 
R.1.1 Identification of CLEC12B 
 For the understanding of NK cell biology it is important to comprehend how the 
balance between activating and inhibiting signals is accomplished. One possibility is the 
existence of receptors with the same specificity but opposite signaling capacities. This 
mechanism has been described for receptors of the C-type lectin like family, which also 
include NKG2D. In order to identify a possible counter-receptor for NKG2D a database 
search was conducted for sequences that showed similarity to the NKG2D extracellular 
domain but contained an inhibitory signaling motif. The search retrieved a mouse cDNA 
clone (AK016908) coding for an unnamed C-type lectin protein product of 275 amino acids 
(BAB30491). Using this sequence as bait, a related human sequence designated human 
macrophage antigen-H (AY358810) was identified. Comparing the sequences, it appeared 
that human macrophage antigen-H (232 amino acids) was missing exon 6, resulting in a 
premature stop codon and an incomplete C-type lectin domain. Searching the genomic DNA 
data base, the missing exon 6, which showed homology to the murine sequence was 
identified. Using primers spanning exons 1 to 6 we identified the complete cDNA coding for a 
276-amino acid type II transmembrane protein (DQ368812) belonging to the C-type lectin 
family of receptors (Robinson et al., 2006; Sobanov et al., 2001). The extracellular domain of 
the putative protein showed highest homology to human NKG2D (36% similarity). A cysteine 
residue in the stalk region might confer dimerization of the molecule as would be typical for 
C-type lectin like receptors (Robinson et al., 2006). However, unlike NKG2D it did not contain 
a charged amino acid in its transmembrane region but an ITIM sequence (VTYATL) in the 
cytoplasmic tail (Fig. 5 A). The genetic locus of this receptor was mapped to human 
chromosome 12p13.2 and mouse chromosome 6qF3 in the vicinity of other C-type lectin-like 
receptors (Fig. 5 B). Overall, the receptor showed a high similarity to CLEC12A (Bakker et 
al., 2004; Han et al., 2004; Marshall et al., 2004) (34% similarity), which was located on the 
same chromosomal locus. This new receptor was therefore named CLEC12B. Using RT- 
PCR expression of CLEC12B was found in human cDNA libraries prepared from various 
tissues except brain (Fig. 5 C). Interestingly, in mammary gland and ovary only a truncated 
splice variant lacking exon 4 could be detected.  
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Fig. 5: Characterization of CLEC12B. A, alignment of the predicted amino acid sequence of human 
and murine CLEC12B with other C-type lectin-like receptors. Asterisks indicate the canonic identical 
amino acids in the C-type lectin-like domain. The intracellular ITIM, transmembrane, and stalk region 
are indicated. B, chromosomal localization of CLEC12B. C, PCR analysis of CLEC12B expression 
(upper panel) using cDNA libraries from human brain (1), colon (2), heart (3), kidney (4), liver (5), lung 
(6), mammary gland (7), ovary (8), spleen (9), testis (10), or water control (11). The first round of 
amplification was performed using primers spanning exons 1 to 6. The resulting product was further 
amplified using primers spanning exons 3 to 5. The expected amplicon size is 384 bp (upper band). 
The lower band (225 bp) represents a splice variant lacking exon 4. Lower panel, actin control. 
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R.1.2 NKG2D and CLEC12B do not recognise the same ligands 
 Due to the high similarity between the NKG2D and CLEC12B extracellular domain it 
might be possible that CLEC12B constitutes an inhibitory counterpart of NKG2D. To test 
whether it recognizes the same ligands as NKG2D, an IgG-fusion protein of the extracellular 
domain of human CLEC12B was produced. Ba/F3 cells, transduced to express the human 
NKG2D ligands MICA, MICB, ULBP1, ULBP2, or ULBP3 were stained at high levels with a 
NKG2D-IgG fusion protein. However, no binding activity of the IgG-fusion protein containing 
the extracellular domain of human CLEC12B could be detected (Fig. 6). This demonstrates 
that there is no apparent overlap in ligand specificity with NKG2D.  
 
 
Fig. 6: NKG2D ligands are not CLEC12B ligands. Ba/F3 cells transduced to express the NKG2D 
ligands displayed in the graphs were stained either with NKG2D-IgG (dashed line) or CLEC12B-IgG 
(bold line) fusion proteins. Filled gray histograms, control staining using secondary and tertiary 
reagents only. Results are representative of two experiments. 
 
A common feature of the NKG2 family members NKG2C and NKG2A is, that they can only 
be expressed at the cell surface in combination with CD94 (Carretero et al., 1997; Han et al., 
2004). To test whether this is also true for CLEC12B, the cDNA of CD94 and various other  
 
 
Fig. 7: CLEC12B surface transport is independent of CD94 expression. A, CD94 and NKG2D 
family members were cotransfected into Hek-293T cells. Surface expression of CD94 was analyzed 
via flow cytometry. B, CLEC12B and CD94 or control DNA were cotransfected into Hek-293T cells 
and surface expression of CLEC12B was stained with an anti-his antibody and analyzed using flow 
cytometry.  
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NKG2 family members were cotransfected into Hek-293T cells. In fig. 7 A CD94 expression 
at the cell surface has been used as a readout and quantified via flow cytometry. In contrast 
to NKG2A, CLEC12B is not able to enhance CD94 transport to the cell surface. Vice versa, 
CLEC12B presentation on the cell surface as measured with an anti-his antibody is 
independent of CD94 cotransfection (Fig. 7 B). 
 
R.1.3 CLEC12B is expressed on myeloid cells 
 To examine endogenous CLEC12B expression and biochemical properties, mouse 
monoclonal antibodies against human CLEC12B had to be generated. Therefore, mice were 
immunized with Ba/F3 cells transfected with CLEC12B. After a boost with recombinant 
CLEC12B-IgG fusion protein mice were sacrificed and spleen cells fused to Ag8 hybridoma 
cells as described in the respective methods section (M.2.3.2). Resulting hybridomas were 
analyzed for production of a suitable antibody with ELISA, flow cytometry and western blot. 
Three hybridoma subclones were selected that specifically recognized the receptor in 
transfected cells either in Western blot (clones 12 and 16, Fig. 8 A and data not shown) or in 
flow cytometry (clones 30 and 16, Fig. 8 B and data not shown).  
 
Fig. 8: Characterization of anti-CLEC12B antibodies. A, the anti-CLEC12B mAb clone 12 
recognizes CLEC12B by Western blotting. Left lane, untransfected NKL lysate; right lane (+), NKL his-
tagged CLEC12B transductant lysate. CLEC12B is detected as a double band. B, the anti-CLEC12B 
mAb clone 30 was tested by flow cytometry on untransfected NKL (upper panel) and NKL transduced 
with his-tagged CLEC12B (lower panel). Filled gray histogram, isotype control staining; bold line, 
staining with anti-CLEC12B mAb clone 30; dotted line, staining with anti-His antibody. 
 
CLEC12B was detected as a double band in Western blot analysis of transfected cells, 
possibly due to differential glycosylation of the receptor. 
 As several C-type lectin like receptors are expressed on myeloid cells (Robinson et 
al., 2006) and expression of CLEC12B could not be detected on lymphocytes (data not 
shown), the human promyelocytic cell line U937 was tested for CLEC12B expression. After 
PMA stimulation of U937 cells strong CLEC12B expression could be detected on the cell 
surface via flow cytometry but not on unstimulated cells (Fig. 9 A). The induction of 
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CLEC12B protein expression was confirmed by Western blot analysis using another anti-
CLEC12B-specific mAb (clone 12) (Fig. 9 B). This indicates that CLEC12B can be expressed 
on monocytic cells after a cell differentiation-inducing stimulus. Interestingly, the endogenous 
CLEC12B protein was detected as a single band as compared with the double band of the 
transfected protein. To further characterize CLEC12B expression in primary cells, CD14+ 
monocytes were purified from human PBMCs. Although no surface expression could be 
detected on freshly isolated monocytes or any other leukocyte population (data not shown), 
surface expression of CLEC12B was demonstrated on in vitro differentiated human 
macrophages (Fig. 9 C). This expression was confirmed by Western blot analysis using three 
independent anti-CLEC12B mAbs (Fig. 9 D and data not shown). 
 
 
Fig. 9: Expression of CLEC12B. A, CLEC12B expression on U937 cells. U937 cells were stimulated 
with 10-8 M PMA for the indicated times, and cells were stained with an isotype control (filled gray 
histograms) or anti-CLEC12B mAb clone 30. Results are representative of three experiments. B, U937 
cells stimulated as described in panel A were lysed and analyzed by Western blotting using the anti-
CLEC12B mAb clone 12 (upper panel) followed by anti-actin blotting to control for equal loading (lower 
panel). C, in vitro differentiated macrophages were stained with an isotype control antibody (filled gray 
histogram) or an anti-CLEC12B mAb (clone 30, bold line). D, freshly isolated CD14+ monocytes 
(Mono) or in vitro differentiated macrophages (MΦ) were analyzed by Western blotting for the 
expression of CLEC12B as described in panel B. 
 
R.1.4 CLEC12B can function as an inhibitory receptor 
 As CLEC12B carries an ITIM sequence in its cytosolic tail an inhibitory function is 
probable. To test the functionality of the ITIM, the tyrosine residue central to this motif was 
exchanged with phenylalanine. The his-tagged wild-type (wt) and the mutant receptors were 
transduced into the NK cell line NKL and surface expression was monitored via flow 
cytometry (Fig. 10, A and B). In a redirected lysis assay against the Fc-receptor positive cell 
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line P815 triggering of NKG2D resulted in efficient NK cell cytotoxicity. This activity could be 
inhibited by co-triggering the CLEC12B wt receptor (Fig. 10 C) but not the mutant receptor 
(Fig. 10 D). It can therefore be concluded that CLEC12B can function as an inhibitory 
receptor and that this activity is dependent on the tyrosine residue enclosed in the ITIM 
sequence. 
 
Fig. 10: Functional analysis of CLEC12B. A and B, His-tagged CLEC12B wild type (A) or ITIM 
tyrosine-to-phenylalanine mutant (B) expression on NKL transductants as determined by anti-his 
antibody staining for detection of CLEC12B. The use of the anti-CLEC12B mAb clone 30 gave 
comparable results. C and D, redirected lysis assay of NKL cells expressing his-tagged CLEC12B wt 
(C) or ITIM mutant CLEC12B (D) against P815 cells. Redirected lysis was stimulated by the indicated 
antibodies (IgG, isotype control antibody). Shown is an effector-to-target ratio of 10:1. Similar results 
were obtained at an effector-to-target ratio of 5:1 (data not shown). Representative of three 
independent experiments. Error bars represent SD of triplicates. 
 
R.1.5 CLEC12B signals through recruitment of SHP-1 and SHP-2 
 ITIMs usually couple to phosphatases to promote inhibitory signaling (Long et al., 
2001). To clarify whether this is also true for CLEC12B, Hek-293T cells were transfected with 
his-tagged wt or mutant human CLEC12B in combination with the phosphatases SHP-1 or  
SHP-2. Transfected cells were treated with pervanadate to inhibit dephosphorylation and 
CLEC12B was immunoprecipitated from lysates using an anti-his antibody.  
Pervanadate treatment induced detectable tyrosine phosphorylation only in the wt 
receptor. Interestingly, the lower band of the transfected CLEC12B detected by Western 
blotting was preferentially phosphorylated (Fig. 11, A and B). Upon phosphorylation the wt, 
but not the mutant receptor, could recruit SHP-1 and SHP-2 as detected by co-
immunoprecipitation (Fig. 11, A and B). This indicates that the inhibitory function of 
CLEC12B can be mediated by the recruitment of SHP-1 or SHP-2 to its ITIM upon receptor 
phosphorylation. 
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Fig. 11: CLEC12B can recruit SHP-1 and SHP-2. Hek-293T cells were transfected with his-tagged 
wt or ITIM mutant (m) CLEC12B in combination with SHP-1 (A) or SHP-2 (B). Cells were treated with 
(+) or without (-) pervanadate (PV). Lysates were immunoprecipitated using control IgG or anti-his 
antibodies, and samples were analyzed by Western blotting for co-immunoprecipitated SHP-1 or SHP-
2 (top panel), phosphorylated CLEC12B (antiphosphotyrosine (P-Tyr), second panel), and total 
immunoprecipitated CLEC12B (anti-CLEC12B mAb clone 12, third panel). To demonstrate 
comparable expression of SHP-1 and SHP-2, lysates were analyzed by Western blotting (bottom 
panel). 
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R.2 NKp30 ligands are downregulated upon cytomegalovirus infection 
 
Evolutionary co-development has lead to a sophisticated interplay between the human 
immune system and HCMV. On the one hand the immune system has developed different 
means of recognizing and clearing HCMV infected cells on the other hand HCMV has 
evolved several strategies of immune evasion. NK cells as a first line of defense take a 
special role in this context (Guma et al., 2006).  
 
R.2.1 Downregulation of NKp30L 
 To examine if HCMV can influence the expression of the putative cellular ligand for 
NKp30 (NKp30L), primary HFFs were infected with the laboratory HCMV strain AD169. 
Three days post infection surface expression of NKp30L was examined by flow cytometry 
with the help of NKp30-ILZ fusion proteins (Stark et al., 2005). NKp30L expression was 
readily detectable on the surface of non-infected HFF (Fig. 12 A). HCMV infected HFF 
showed a clearly reduced surface expression of NKp30L. The same effect was observed 
when infecting MRC5 lung fibroblasts (data not shown).  
 
 
Fig. 12: Modulation of NKp30L in HCMV infection. A, FACS staining of NKp30 ligand (NKp30L) on 
non-infected and on AD169-infected HFF three days post infection. Grey shadow: control staining with 
CS1-ILZ; bold line: non-infected HFF; dashed line: AD169-infected HFF. B, Immunofluorescence of 
non-infected and AD169-infected HFF three days post infection. Cells were stained with NKp30-ILZ 
and with CS1-ILZ as a control. Nuclei were counterstained with DAPI. Arrowheads indicate high 
density of NKp30L staining. Results are representative of at least three experiments. 
 
 
To further analyze the reduced surface expression of NKp30L after HCMV infection 
immunofluorescence staining was performed on non-infected and HCMV-infected HFF. In 
contrast to a control ILZ-fusion protein, NKp30-ILZ produced a uniform staining in non-
infected HFF (Fig. 12 B). In HCMV infected HFF we observed a more clustered staining 
preferentially in perinuclear regions (Fig. 12 B, arrowheads). This suggests that HCMV 
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infection results in an intracellular retention of NKp30L, possibly explaining its reduced 
surface expression.  
Laboratory HCMV strains can differ substantially from wild type isolates, a fact which has 
been demonstrated for the resistance of infected cells to NK cell lysis (Cerboni et al., 2000). 
To exclude that the observed influence of HCMV on NKp30L is an artifact from the use of the 
laboratory strain AD169, we performed experiments using two wild type HCMV strains. The 
clinical HCMV isolates also induced a clear down-regulation of NKp30L on infected HFF (Fig. 
13 A and B), demonstrating that this effect on NKp30L surface expression may also be 
relevant in naturally occurring infections. 
 
 
Fig. 13: Wild type HCMV down-modulates NKp30L expression. HFF were non-infected or infected 
with a HCMV wild type isolate. Three days post infection NKp30L expression was analyzed by FACS 
staining. Grey shadow: control staining with CS1-ILZ; bold line: non infected HFF; dashed line: wild 
type-HCMV infected HFF. Results are representative of three (A) and two (B) independent 
experiments with two different wild type isolates. Differences in NKp30L staining intensity are due to 
different HFF preparations.  
 
R.2.2 An immediate early/early HCMV gene product is responsible for NKp30L down-
regulation 
 Down-regulation of NKp30L could either be due to a cellular process initiated upon 
viral entry like an interferon response (Pichlmair and Reis e Sousa, 2007) or due to a viral 
gene product that actively interferes with NKp30L presentation. To investigate this, AD169 
viral particles were inactivated by UV-irradiation and used to infect HFF. UV-irradiation cross-
links the viral DNA, making transcription and replication impossible but leaving the 
proteinaceous components of the virus intact. This treatment abrogated the effect of HCMV 
on NKp30L down-modulation (Fig. 14). Hence, some HCMV gene product has to be 
expressed de novo after infection of the cell to cause the observed effect.  
In order to identify that putative gene product three HCMV deletion mutants were created, 
WaBAC1, WaBAC2 and WaBAC3 based on the AD169 bacterial artificial chromosome 
(BAC) pHB5 (Borst et al., 1999). In this BAC the genes US2 to US6 have been replaced by 
the BAC-cassette. Fig. 15 A depicts a schematic overview over the HCMV genome and the 
deleted regions. 
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Fig. 14: UV-inactivation of HCMV abrogates NKp30L down-modulation. HFF were infected either 
with control virus or with UV-irradiated HCMV particles. Staining was done on day three post infection. 
Grey shadow: control staining with CS1-ILZ; bold black line: non-infected HFF; dashed line: AD169-
infected HFF; bold grey line: HFF infected with UV-inactivated AD169 particles. 
 
WaBAC1 lacks the region from TRS1 to UL20. Here, many open reading frames (ORF) can 
be found whose function has not yet been described. However, this deletion mutant still 
retained the ability to down-modulate NKp30L surface expression (Fig. 15 B). In WaBAC2 
the ORFs comprising IRL14 to US6 were deleted. This region encompasses most of the 
genes implicated in MHC I down-regulation (Mocarski, 2004). As shown in Fig. 15 C, down-
modulation of NKp30L was still possible in the absence of these genes. WaBAC3 has a 
deletion in the region from US2 to US25, which also contains immunomodulatory and many 
undescribed genes. The resulting virus WaBAC3 showed some growth defects and had to be 
concentrated to achieve the same MOI as for the other viruses. However, the deletion had no 
influence on NKp30L down-modulation upon infection (Fig. 15 D). The differences in the 
extent of the NKp30L down-modulation between the deletion mutants were not significant 
(data not shown). The creation of further virus deletion mutants was hampered by the fact 
that essential genes for the replication of HCMV would be affected. 
 
Fig. 15: Analysis of HCMV deletion mutants. A, schematic representation of the HCMV genome 
and the respective deleted regions. All mutants lack the genes US2-US6 where the BAC-cassette was 
inserted (BAC). Black horizontal bars indicate the respective deleted regions. TRL: terminal repeat 
long; UL: unique long; IRL: inverted repeat long; IRS: inverted repeat short; US: unique short; TRS: 
terminal repeat short.  B-D, NKp30L staining after infection with respective virus mutant. Grey shadow: 
control staining with CS1-ILZ; bold black line: non infected HFF; dashed line: virus infected HFF; B 
WaBAC1: deletion of TRL1-UL20. C WaBAC2: deletion of IRL14-US1. D, WaBAC3: deletion of US7-
US25. Results representative of at least three experiments for each virus mutant. 
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HCMV genes are expressed in a timely ordered fashion. In order to narrow down further 
candidates we inhibited different stages of the HCMV replication cycle. First, the translation 
of immediate early and early genes was inhibited via cycloheximide and actinomycin D 
treatment. Second, the late replication stage of HCMV was blocked by inhibiting the HCMV 
polymerase with phosphonoformate. Because of the toxicity of these inhibitors, cells had to 
be analyzed 20 h post infection to produce reliable results. At this time of infection the effect 
on the surface expression of NKp30L was detectable (Fig. 16 A), but less pronounced 
compared to three days post infection (Fig. 12). Blocking late HCMV genes by treatment with 
phosphonoformate did not affect the down-regulation of NKp30L after HCMV infection (Fig. 
16 C). Blockade of the immediate early and early infection phase lead to some reduction of 
NKp30L surface expression already in non-infected HFF (Fig. 16 B). However, no additional 
inhibition could be observed after HCMV infection. Fig. 16 D depicts the inhibition of NKp30L 
expression upon infection calculated from the MFI. Statistical analysis was performed using 
one-way ANOVA. The inhibition of the IE phase of infection led to a significant reduction of 
NKp30 downregulation (P<0.01). This indicates that an immediate early/early HCMV gene 
might be responsible for NKp30L down-modulation. 
 
 
Fig. 16: Inhibition of HCMV infection stages. HFF were treated as described in the materials and 
methods section to inhibit immediate early and early gene transcription (IE) and late gene expression 
(L). Cells were harvested 20 h post infection and stained for NKp30L expression. Grey shadow: 
control staining with CS1-ILZ; bold black line: non infected HFF; dashed line: AD169 infected HFF. 
Results representative of five independent experiments. 
 
R.2.3 Reduced NKp30-dependent NK cell lysis of HCMV infected fibroblasts 
 Next, the functional consequences of fibroblast HCMV infection on NK cell killing 
activity were determined. HCMV infection results in a down-modulation of MHC I surface 
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expression ((Mocarski, 2004) and data not shown), thereby reducing NK cell inhibition. This 
might counteract any possible influence of NK cell activation through the modulation of 
NKp30L expression. In order to reduce the effect of MHC I modulation on NK cell activity we 
used the NK cell line NK92C1, which lacks the expression of any functional inhibitory KIR or 
CD94/NKG2A receptors (Komatsu and Kajiwara, 1998). As shown in Fig.17 B, NK92C1 
readily lysed non-infected HFF. This lytic activity was partially blocked by the addition of anti-
NKp30 antibodies, demonstrating that the lysis of HFF by NK92C1 is dependent on NKp30 
triggering. With AD169 infected HFF the lysis by NK92C1 was reduced compared to non-
infected cells and anti-NKp30 antibodies no longer blocked lysis (Fig. 17 C). This is 
consistent with the observed down-regulation of NKp30L in the infected cells (Fig. 17 A) and 
demonstrates that the reduction in NKp30L as detected by flow cytometry has also functional 
consequences for NK cell killing. 
 
 
Fig. 17: Down-modulation of NKp30L has functional consequences. A, HFF were infected with 
AD169 and NKp30L expression was determined three days post infection. Grey shadow: control 
staining with CS1-ILZ; bold black line: non infected HFF; dashed line: AD169 infected HFF. B, C, The 
same cells were analyzed in a chromium release assay using NK92-C1 cells as effectors and non 
infected (B) or AD169 infected (C) HFF as targets. IgG control or anti-NKp30 antibody were added to 
a final concentration of 10 µg/ml. Filled diamonds: IgG-control; open squares: anti-NKp30 antibody. 
Error bars indicate SD. Representative of four independent experiments. 
 
In another strategy to avoid the effect on MHC I expression by HCMV, the deletion mutant 
WaBAC1 was used the for infection. In contrast to AD169 this virus was no longer able to 
down-regulate MHC I molecules from the surface of infected cells. Instead, a slight up-
regulation was to be observed, probably due to an interferon-response (data not shown). 
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This made it possible to use primary IL-2 activated NK cells for the functional assay. As 
shown in Fig. 18 B lysis of non-infected HFF was less dependent on NKp30 as with the 
NK92C1 cell line, which is likely due to the presence of the full set of activating receptors on 
primary NK cells. Nevertheless, lysis was still blocked significantly by the addition of anti-
NKp30 antibodies. Similar to the experiment with AD169 and NK92C1 cells, HFF infected 
with the mutant WaBAC1 HCMV showed reduced lysis by primary IL-2 activated NK cells 
and this lysis was no longer blocked by the addition of anti-NKp30 antibodies (Fig. 18 C). 
This change in NK cell reactivity against infected HFF correlated again with the observed 
down-modulation of NKp30L upon HCMV infection (Fig. 18 A). 
 
 
Fig. 18: Reduced NKp30-dependend lysis of HCMV infected HFF by primary NK cells. A, HFF 
were infected with AD169 and NKp30L expression was determined three days post infection. Grey 
shadow: control staining with CS1-ILZ; bold black line: non-infected HFF; dashed line: AD169-infected 
HFF. B, C, The same cells were analyzed in a chromium release assay using primary IL-2 activated 
NK cells as effectors and non-infected (B) or HCMV-infected (C) HFF as targets. IgG control or anti-
NKp30 antibody were added to a final concentration of 10 µg/ml. Filled diamonds: IgG-control; open 
squares: anti-NKp30 antibody. Error bars indicate SD. Representative of three independent 
experiments 
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R.3 Identification of NKp30 ligands 
 
R.3.1 Heparan sulfate is not the ligand for NKp30 
 The involvement of heparan sulfate structures as a possible NKp30 ligand is 
controversially discussed (Bloushtain et al., 2004; Warren et al., 2005). Both groups used the 
hamster derived cell line CHO as a model system. Central to this approach are several CHO 
mutants lacking different proteoglycans (Esko, 1991). To finally shed light on the identity of 
the cellular NKp30L it was necessary to establish the role of heparan sulfate as NKp30 
ligand as part of this thesis. 
 The first step was to reproduce the results of the previously published papers. As 
described by Bloushtain et al, staining with NKp30-ILZ fusion proteins was strongly but not 
completely reduced on the CHO mutant pgsA-745 (Fig. 19 A). This cell line lacks the enzyme 
xylosyltransferase and is therefore proteoglycan deficient. The same experiment was 
conducted with CHO cells obtained from Hillary Warren and Angel Porgador with identical 
results (data not shown). Hence, the differences in the published results are not caused by 
the use of unequal cell lines. The reduced staining intensity on CHO pgsA-745 might indicate 
that NKp30 fusion proteins show a high affinity for polysaccharide structures.  
 
 
Fig. 19: Experiments in CHO cells are biased. A, wt CHO cells (bold line) and proteoglycan 
deficient CHO pgsA-745 (dashed line) were stained with NKp30-ILZ fusion proteins (left panel) and 
with anti-heparan sulfate antibody (right panel). B, cytotoxicity assay. Lysis of CHO wt (K1) and CHO 
pgsA-745 by NK92C1 was blocked by addition of anti-NKp30 or control antibody. Error bars represent 
SD of triplicates. Shown is one representative experiment of two. 
 
 
As fusion protein binding does not necessarily indicate the existence of functional NKp30L 
this was tested via a cytotoxicity assay. Lysis of the wt CHO cells (labeled K1) could be 
inhibited by addition of anti-NKp30 antibody. Therefore NK cell activation by these cells is 
dependent on NKp30 engagement. The same result was seen when CHO pgsA-745 were 
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used as target cells, despite their reduced fusion protein binding capacities (Fig. 19 B). This 
means that the same amount of functional NKp30L can be found on both cell lines, wt and 
mutant. In conclusion, it seems that activation of NK cells through NKp30 is not influenced by 
the lack of proteoglycan structures. The fact that the results from the fusion protein staining 
did not fit the functional data obtained from the killing assays might be due to unspecific 
binding of the fusion proteins. This does not seem unexpected as hamster cells are 
evolutionary far away from human cells and probably display a very different surface 
structure. 
 Therefore, the following experiments were carried out on human cell lines. Here, the 
influence of heparan sulfate residues on fusion protein binding was explored as well. A first 
attempt to silence xylosytransferase expression via an siRNA approach failed (data not 
shown). Hence, it was tested whether heparan sulfate would work to block NKp30 activation. 
NKp30L positive Hek-293T cells were stained with NKp30 ILZ- and IgG-fusion proteins with 
addition of 10 µg/ml heparan sulfate or chondroitin sulfate as a control. Neither 
polysaccharide could inhibit the binding of the respective fusion protein (Fig. 20 A) while 
binding of an anti-heparan sulfate antibody was strongly inhibited at the concentration used 
(data not shown). In another approach Hek-293T cells were treated with heparinase III that 
specifically cleaves heparan sulfate residues. Removal of heparan sulfate residues was 
confirmed by staining with an anti-heparan sulfate antibody (data not shown). As a control, 
cells were treated with hyaluronidase. No influence on fusion protein binding could be 
detected (Fig. 20 B).  
 The data obtained with fusion proteins was further confirmed via functional assays. 
As shown in fig. 20 C, addition of heparan sulfate to a cytotoxicity assay did not yield a 
functional effect on the activity of primary NK cells. The same was true for the addition of 
heparin or chondroitin sulfate. Lysis was also not inhibited when target cells were 
preincubated with heparinase III or hyaluronidase before addition to the assay (Fig. 20 D). 
Hence, it is very improbable that heparan sulfate constitutes a functional cellular ligand for 
NKp30. 
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Fig. 20: Heparan sulfate does not mediate functional effects through NKp30. A, Hek-293T cells 
were stained with NKp30-ILZ or -IgG fusion proteins in the presence (dashed lines) or absence (bold 
lines) of heparan sulfate (lower panels) or chondroitin sulfate (upper panels) as a control. B, Hek-293T 
cells were treated with hyaluronidase (upper panels) or heparinase III (lower panels) for 2 h at 37°C 
and then stained with NKp30-ILZ or –IgG fusion proteins. C, Heparin, heparan sulfate (HS) or 
chondroitin sulfate (CS) were added to a cytotoxicity assay of primary NK cells against Hek-293T cells 
at a concentration of 10 µg/ml. D, NK92C1 were used in a cytotoxicity assay against Hek-293T cells 
that were preincubated with heparinase III or hyaluronidase for 2 h at 37°C. Error bars represent SD of 
triplicates. 
 
R.3.2 Characterization of NKp30L 
 If heparan sulfate does not constitute the functional NKp30L, the nature of the NKp30 
ligand is still undefined. Further experiments were conducted to find out more about the 
characteristics of the elusive molecule. On the one hand Hek-293T cells were trypsinized to 
explore whether NKp30L would also involve a proteinacious component. As shown in Fig. 
21A trypsinization reduces binding of NKp30-ILZ fusion proteins to the cell surface 
considerably. This effect is almost completely reverted when the cells are incubated for 4 h at 
37°C before the staining procedure (Fig. 21 B).  
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 These results could also be confirmed with a cytotoxicity assay. As depicted in fig. 21 
C, trypsinization of Hek-293T cells led to a significant reduction of NK92C1 activity. Addition 
of anti-NKp30 antibody reduced the lysis of both targets to almost zero. The remaining lysis 
of the trypsinized cells most probably is mediated through residual NKp30L that is brought to 
the surface during the course of the cytotoxicity assay. This might also hint to a rather high 
turnover rate of the putative ligand. 
 
Fig. 21: NKp30L is trypsin sensitive. A, B, Hek-293T cells were control treated (bold lines) or 
incubated with trypsin for 10 min (dashed line) and stained immediately(A) or incubated for 4 h at 
37°C before the staining procedure (B). C, Hek-293T cells were control treated (EDTA)  or trypsinized 
and used as targets in a cytotoxicity assay with NK92C1 cells. Lysis was blocked with anti-NKp30 
antibody. Error bars represent SD of triplicates.   
 
 
Fig. 22: NKp30L is regulated in a cell cycle dependent manner. Hek-293T cells were arrested in 
M-phase using 100 ng/ml nocodazole or 0.1 µM colchicine. A, PI staining of treated cells to show DNA 
content. DMSO and 10 µM colchicine for 1 h were used as a control. B, NKp30L staining of cells 
treated with colchicine. C, NKp30L staining of cells treated with nocodazole. Representative of at least 
three independent experiments. 
 
Recently, it has been shown that NK cells preferentially adhere to cells going through mitosis 
(Nolte-'t Hoen et al., 2007). The NCR NKp46 has been implicated in this process. Hence it 
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became interesting to query the role of the NCR NKp30 in dividing cells. Hek-293T cells were 
arrested in M-phase with two different inhibitors, either colchicine or nocodazole. Cell cycle 
arrest was confirmed through staining with propidium iodide (PI, fig. 22 A). Both colchicine 
(Fig. 22 B) and nocodazole (Fig. 22 C) treatment led to a reduced surface staining of 
NKp30L. Thus it seems that contradictory to the NKp46 ligand, NKp30L is downregulated 
during mitosis. 
 
R.3.3 Identification of NKp30L through an siRNA library 
 As attempts to identify NKp30L with common methods like expression cloning or 
biochemical approaches have failed so far, NKp30L might not consist of a single protein 
component but rather a complex structure or enzymatic modification. Therefore, a siRNA 
library was chosen as the appropriate method because complex structures can be disrupted 
upon loss of a single component.   
 The human Epstein-Barr-virus (EBV)-transduced B-cell line EM-3 was selected for 
this process as it  expresses NKp30L (Byrd et al., 2007) and does not seem to mediate any 
unspecific effects in fusion protein binding as has been observed for other cell lines. Fig. 23 
shows a scheme of the transduction and selection process. 
 
 
Fig. 23: schematic overview over the transduction and enrichment process of the siRNA 
library. EM-3 cells were infected with lentiviral particles containing the siRNA libray and a puromycin 
selction marker. After selection NKp30L negative EM-3 cells were enriched via NKp30-IgG fusion 
protein staining and subsequent depletion using the Miltenyi MACS technology and FACS-sorting. 
From the enriched population total RNA was purified and analyzed for enriched siRNAs. 
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 The commercially available siRNA library human 50K was transduced into EM-3 cells 
with the help of prepackaged lentiviral particles and selected with puromycin (Fig. 23, step 1). 
The resulting population was enriched for cells that had downregulated NKp30L via NKp30-
IgG fusion protein staining and depletion using the MACS system as described in the 
material and methods section. A second MACS selection step was followed by two further 
rounds of enrichment by fluorescence activated cell sorting (FACS) (Fig. 23, step 2). 
Expression of NKp30L in the whole cell population was controlled via flow cytometry as 
shown in fig. 24 A-C. In addition, subclones were produced through limiting dilution and 
analyzed for their ligand expression by flow cytometry. To verify flow cytometric data, a 
cytotoxicity assay was performed. As shown in fig. 24 D, a slight downmodulation of the lytic 
activity could be observed that also correlated with the respective fusion protein staining. 
 
Fig. 24: Depletion of NKp30L positive cells. A-C, NKp30-IgG fusion protein staining at different time 
points after EM-3 depletion. Bold line, positive fraction; dashed line, negative fraction; grey shadow, 
control fusion protein staining. A, staining directly after the second depletion with MACS beads. B, 
staining 5 days after the second depletion. C, 2 weeks after two additional depletions using FACS. D, 
cytotoxicity assay to test for functional consequences of NKp30L downmodulation. Primary NK cells 
were tested against EM-3 subclones shortly after second depletion. E shows the according fusion 
protein stainings. Error bars represent SD of triplicates. 
 
 As can be seen in fig. 24 A-C, the expression level of NKp30L in the depleted cell 
population returned to that of the control treated population two weeks after the last 
depletion. The previously generated subclones lost the downmodulation of NKp30L as well 
(data not shown). The depletion process most probably was successful and siRNAs inhibiting 
NKp30L expression were enriched. However, after some time the effect of the siRNA might 
have worn off, probably due to adjustment of the cells to the new conditions. 
Following the selection process, total RNA was prepared from the subclones. After reverse 
transcription into cDNA the siRNA transcripts were amplified via flanking primer pairs and 
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sequenced. Of 55 clones that grew out, 33 could be sequenced and of these 28 yielded a 
target sequence. Sequences were aligned to the siRNAs found in the human 50K library and 
to the human genomic transcript using blast analysis. Some of the target sequences occured 
several times which indicates that the enrichment process was successful (table 1). 
 
occured putative target gene 
9x Homo sapiens ADP-ribosylation factor related protein 1 (ARFP1) 
5x Homo sapiens SNW domain containing 1 (SNW1),  
3x Homo sapiens hypothetical protein FLJ21272 (FLJ21272),  
3x Homo sapiens exosome component 2 (EXOSC2) 
2x Homo sapiens apoptotic peptidase activating factor 1   
2x Homo sapiens multiple substrate lipid kinase (MULK),  
2x Homo sapiens lysozyme-like 6 (LYZL6), mRNA 
1x 745 275 AA641796 EST  
1x BC027448 Similar to granule cell antiserum positive 8, clone MGC:34919  
1x Homo sapiens chromosome 3 open reading frame 27 
 
Table 1: Summary of the sequences obtained in the siRNA selection procedure. EM-3 cells were 
lysed and total RNA was prepared. After reverse transcription the siRNA product was amplified by 
PCR and sequenced. Resulting sequences were aligned using NCBI blast and the data delivered with 
the library. 
 
 The clear advantage of the SBI siRNA library is that the siRNA sequences were 
designed to fit the affimetrix GeneChip Human Genome U133 Plus 2.0 array. Hence, 
additionally to sequencing of the subclones, total RNA was isolated from control treated EM3 
and depleted EM3 cells. After reverse transcription into cDNA, siRNA was prepared using 
nested PCR as shown in fig 25.  
  
 
Fig.25: Amplification of siRNA fragments for microarray analysis. PCR-product of the siRNA 
amplification was loaded onto a 2% agarose gel. After the first round a product of about 200 bp was 
obtained. The second amplification yielded a fragment of 100 bp that contained only the functional 
siRNA strand of the hairpin sequence. After exonuclease digestion of the nonbiotinylated strand the 
single stranded DNA was hybridized to an affimetrix gene chip set. EM3: untransduced EM3 cells; 
control: no template.  
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 The resulting DNA fragments were subjected to lambda exonuclease digestion to 
remove the nonbiotinylated antisense strand and the single-stranded and biotinylated 
product was hybridized to an affimetrix gene chip array. To ensure that results were 
representative the amplification and hybridization process was repeated and lead to almost 
identical outcome. The data obtained was analyzed applying the genenet data analysis 
software provided by SBI. To compare both samples, relative expression of the siRNAs 
expressed in the control treated cells were compared to the expression in the NKp30L 
depleted cells as shown in a dot plot in fig 26. In fig. 26 A it is clearly visible that many siRNA 
species are expressed in the control population but completely absent in the depleted 
population. These siRNAs were lost during the depletion process and probably play no role 
for NKp30L expression. Dots found along the red diagonal are expressed equally in both 
populations. The interesting siRNAs are represented by dots that lie above the red diagonal. 
These show a higher expression in the NKp30L negative population than in the control. 
These are the siRNAs that were enriched and are most probably involved in NKp30L 
expression. 
 
Fig. 26: Dot plot displaying the relative expression levels of detected siRNAs. A, Graph of the 
relative siRNA expression within the two different populations. Dots found above the red diagonal 
should be selectively enriched and therefore indicate a possible relation to NKp30L. B, siRNA 
expression is displayed as relative fluorescence value in the control treated cell population (x-axis) 
versus the selected cell population (y-axis). Due to the size of the data file only positive hits above the 
red diagonal are shown. Red circles and numbers refer to table 2. Numbers that appear twice denote 
that two individual siRNAs directed against the same molecule could be detected.  
 
 Fig. 26 B shows the distribution of the best hits on a linear scale as derived from 
another software. Here, only the best 2000 hits are shown, that are found all in the relevant 
section of the graph.  
 Depending on where the threshold is set there are 300-500 interesting siRNAs found 
to be selectively enriched in the NKp30L depleted population. Many of these hits are 
intracellular proteins that might probably be involved in NKp30L regulation or transport to the 
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cell surface. Because of the wealth of information obtained by using a microarray based 
approach it is not possible to list all genes of interest. Table 2 denotes some interesting 
molecules, either transmembrane, secreted or involved in cancer progression that have 
yielded a high score in the comparison between the control sample and the depleted sample. 
Dots represented by these proteins in fig. 26 are marked with red circles.  
 Two molecules, CD151 and ICAM5 were found to be represented by two different 
siRNAs that were enriched independently. This increases the probability that these 
molecules are related to NKp30L. These and the other proteins shown in the table will be 
subjected to further investigation.  
 
# Value GeneBank# Gene name 
1 22604 g4557540 dystonia 1, torsin A 
2 14870 g4758811 natural killer cell transcript 4, IL32 
3 13313 g12545403 intercellular adhesion molecule 5 (ICAM5) 
4 11290 g4757941 CD151 antigen (CD151) 
5 22706 g4758109 HLA-B associated transcript-3, BAT3 
6 24166 g9966904 Homo sapiens lysozyme homolog (LOC57151), mRNA.  
7 18171 g13325360 Homo sapiens, major histocompatibility complex, class I, C 
 
Table 2: Educated guess of interesting molecules retrieved from the siRNA screen after analysis of 
the microarray data. # refers to numbers given in fig. 26. Value depicts relative expression in the 
NKp30L depleted cell population.  
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D. Discussion 
 
D.1 Identification of CLEC12B 
 
 Originally identified during a database search, CLEC12B first appeared as a good 
candidate for an inhibitory counterpart for NKG2D. Due to the high homology in the 
extracellular domains of the receptors and the converse signaling motifs a functional 
relationship between these two molecules seemed possible. CLEC12B can be transported to 
the cell surface in a manner that is independent of CD94 (Fig. 7). Hence, there is no 
functional similarity between NKG2A or NKG2C and CLEC12B. Using IgG-fusion proteins it 
became clear that NKG2D ligands are not recognized by the CLEC12B extracellular domain. 
Of course it cannot be excluded that there are more, yet undescribed NKG2D ligands that 
might bind to CLEC12B. But, in contrast to NKG2D, expression of the CLEC12B protein 
could also not be detected on NK , NKT or T cells. Therefore, it seems highly unlikely that 
CLEC12B would in any way be functionally related to NKG2D.  
 
D.1.1 CLEC12B functions 
 Examination of the functional properties of CLEC12B lead to the result that this 
receptor is able to transmit an inhibiting signal via the tyrosine residue embedded in its ITIM. 
Upon phosphorylation of this motif, the phosphatases SHP-1 and SHP-2 were recruited to 
the receptor as shown by co-immunoprecipitation. The signal was able to inhibit an activating 
signal delivered simultaneously through NKG2D. Signals from other activating NK cell 
receptors such as 2B4 (Bhat et al., 2006) could be influenced by the inhibitory effect of 
CLEC12B as well (data not shown), demonstrating that CLEC12B can inhibit a broad range 
of receptor mediated activating signals. In preliminary experiments the function of 
endogenous CLEC12B was investigated on PMA treated U937 cells. Stimulation of these 
cells with lipopolysaccharide (LPS) induced the production of tumor necrosis factor α 
(TNFα). However, engagement of CLEC12B by plate-bound anti-CLEC12B antibody did not 
significantly inhibit LPS-induced TNFα production (data not shown). The reason for this 
might be that the plate bound CLEC12B antibody was not able to counteract the signal of the 
soluble LPS. While plate bound CLEC12B antibody would stimulate the cells only in a 
specific contact zone the soluble LPS can stimulate the cells all over their surface. It is 
therefore likely that the local inhibitory effect of CLEC12B engagement was not sufficient to 
counteract the more global LPS signal. This demonstrates that CLEC12B is only potent in 
blocking cellular activation when it is co-engaged with an activating receptor in a defined 
region of the plasma membrane of a cell.  
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D.1.2 Endogenous CLEC12B expression 
 By RT-PCR, CLEC12B expression on the mRNA level has been detected in almost 
every tissue except brain. In contrast to that finding, CLEC12B expression on the cell surface 
as detected with monoclonal antibodies could only be found on monocyte derived 
macrophages. This contradiction can be explained with the assumption that macrophages 
can be found throughout all tissues. Hence, tissue cDNA libraries would also contain 
macrophage cDNA. This notion would also explain the lack of CLEC12B expression in the 
brain. In a healthy individual the blood-brain-barrier does not allow immune cells to enter the 
brain tissue. CLEC12B expression could also not be detected on monocyte derived dendritic 
cells or blood leukocytes. This leads to the conclusion that CLEC12B is probably exclusively 
expressed on macrophages that are usually not found in the blood stream. 
 Another interesting finding was that in mammary gland and ovary only a truncated 
variant of CLEC12B lacking exon 4 could be detected. As this exon encodes a part of the 
extracellular domain essential for formation of a functional C-type lectin-like domain, the 
resulting receptor would probably be nonfunctional. It will be interesting to investigate the 
regulation of this differential splicing of CLEC12B in different tissues. 
 CLEC12B may be involved in limiting the activity of monocyte-derived immune cells 
after cell differentiation and possibly during inflammatory diseases. As there is a CLEC12B 
homologue in mice it might also be interesting to investigate CLEC12B function in one of the 
many disease and infection models for this animal. This will probably also give us valuable 
information about CLEC12B function in human diseases. Another important issue is to 
identify the still unknown ligand of this receptor. This might give more insight into the 
biological function of this novel molecule. 
 
D.2 Human Cytomegalovirus downregulates NKp30L  
 
D.2.1 Downmodulation of NKp30L might be a new immune evasion mechanism 
 The NCR play an important role in the regulation of NK cell activity (Moretta and 
Moretta, 2004). Their putative cellular ligands can be found on various tumor cells (Arnon et 
al., 2006) but also on primary untransformed fibroblasts as reported here. Unraveling the 
identity of these ligands will greatly advance our understanding of NK cell regulation through 
activating structures on tumors and infected cells. Heparan sulfate structures have been 
postulated to bind NKp30 (Bloushtain et al., 2004) but other groups could not reproduce 
these results (Warren et al., 2005). The data presented in this thesis suggests that heparan 
sulfate is not involved in functional activation of NKp30 during the NK cell-mediated lysis as 
described in chapter R.3.1. 
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 Fig. 12 shows that NKp30L is downregulated upon HCMV infection. This has not only 
been demonstrated with the help of fusion proteins but also by functional effects on the 
cytotoxicity of NK92C1 and primary NK cells. Lysis of HFF infected with HCMV could no 
longer be inhibited by addition of blocking anti-NKp30 antibody. This means that NK cells 
were no longer activated through NKp30. Additionally, overall lytic activity was less against 
infected HFF. Because NKp30 is an important receptor for NK cell activation it is not 
implausible that a pathogen like HCMV which shares such a long history of co-evolution with 
humans has evolved an escape mechanism from recognition by this receptor. Clinical HCMV 
isolates could be shown to downmodulate NKp30L expression as well. Therefore, this 
phenomenon is not an artifact of the laboratory cultivation of AD169 but seems to play a role 
in vivo.  
 Modulation of NKp30L by viral infection has been shown for other viruses as well. 
Infection of HFF with vaccinia virus leads to up-regulation of NCR ligands on the target cell 
and higher NK cell activity (Chisholm and Reyburn, 2006). Similar findings have been 
reported for HSV-infected cells (Chisholm et al., 2007). This indicates that there could be an 
antiviral response in infected cells leading to the up-regulation of NCR ligands. HCMV might 
have evolved a strategy to evade this response by down-modulation of NKp30L. It has 
already been described that HCMV expresses an inhibitor of NKp30, pp65/UL83 (Arnon et 
al., 2005). This viral tegument protein is reported to be secreted from infected cells and to 
disrupt NKp30 signaling. However, it is improbable that pp65 is responsible for the effects 
observed in this study. Cells were washed before staining with NKp30-ILZ. Therefore, 
secreted proteins would have been removed, making it unlikely that secreted pp65 blocks the 
binding of NKp30-ILZ. Furthermore, the supernatant of HCMV infected cells did not lead to 
inhibition of NK cell activity (data not shown). Additionally, pp65 is only strongly expressed in 
the late infection phase (McLaughlin-Taylor et al., 1994). The experiments in fig. 16 point to 
an immediate early/early HCMV protein as responsible mediator. As HCMV encodes multiple 
immunomodulatory proteins it might well be possible that there is more than one mechanism 
to escape NKp30 activation.  
 
D.2.2 How is NKp30L downmodulated? 
 Revelation of the HCMV gene product responsible for NKp30L down-regulation might 
also help in the discovery of the identity of the cellular NKp30L. For heparan sulfate only a 
minor downregulation could be detected upon HCMV infection. This finding strengthens the 
theory that heparan sulfate is not involved in NKp30L recognition. Using NKp30-ILZ fusion 
proteins in immunofluorescence a different staining pattern for NKp30L in non-infected and 
AD169-infected HFF could be shown (Fig. 12 B). The perinuclear intracellular distribution of 
NKp30L in infected HFF might be a hint, that the ligand is held back in intracellular 
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compartments instead of being transported to the cell surface. This strategy is already 
employed by HCMV, as MHC I molecules are held back and dislocated from the 
endoplasmic reticulum by gene products of the US region (Mocarski, 2004). In our case, 
these genes do not seem to be involved in the retention of NKp30L as all three deletion 
mutants tested did not abrogate NKp30L down-regulation. Therefore we are able to exclude 
the HCMV ORFs TRL1 to UL20 and IRL14 to US20. Furthermore, the additional genes 
(UL133 to UL151) of HCMV wild-type isolates are excluded, since they are deleted in the 
laboratory strain AD169 (Cha et al., 1996). Genes lying within the repeat containing regions 
in WaBAC1 and WaBAC2 cannot completely be excluded as they exist in a second copy 
within the HCMV genome. Our data show that the putative responsible HCMV gene is a 
newly produced gene product from the HCMV genome during the immediate early or early 
infection phase. As many of these genes are essential for HCMV replication, it is not possible 
to generate simple deletion mutant viruses for these genes. We therefore expressed different 
HCMV ORFs in the cell lines Hek-293T and HeLa that are also known to carry NKp30L. 
Among those were the genes encoding the important immediate early proteins IE1 and IE2 
(UL123 and UL122). Transfection of these genes had no significant effect on NKp30L 
expression (data not shown). However, it is also possible that not one single gene mediates 
the described effect on NKp30L surface expression, but a combination of genes that could 
compensate for the knockout in a single deletion mutant and which is impossible to recreate 
by the transfection of individual HCMV genes. Combination of deletion mutants or the 
expression of several HCMV gene products may be necessary to identify the gene(s) 
responsible to the down-modulation of NKp30L in future studies. Another possibility would be 
that the nature of the NKp30L expressed on HFF and tumor cells like Hek-293T and HeLa 
differ in some way. Then the designated HCMV gene product also might not have an effect 
on NKp30L expression.  
 One would predict that murine cytomegalovirus would not need to possess the ability 
to down-modulate the expression of NKp30L, as the NKp30 and NKp44 receptors do not 
exist in mice. This is also the reason why it was not possible to recreate our experimental 
settings in an in vivo situation.  
 Interestingly, we did observe the expression of the putative NKp44 ligand on HFF by 
using an NKp44-ILZ protein and this expression was also down-regulated upon HCMV 
infection (data not shown). Possibly, HCMV is also able to downregulate NKp44 employing 
the same strategy as for NKp30. Due to nonfunctional NKp46 fusion proteins it was not 
possible to detect any ligand for NKp46 on the surface of HFF, and could therefore not 
determine if HCMV also has the ability to interfere with NKp46 ligand expression. 
 HCMV infection leads to the down-regulation of MHCI molecules from the surface of 
infected cells ((Mocarski, 2004) and data not shown). This would result in a reduced 
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inhibition of NK cells and enhanced NK cell-mediated lysis of infected cells. To counteract 
this, HCMV has evolved several strategies. While expressing viral ligands for inhibitory 
receptors, HCMV gene products also interfere with the expression of ligands for the 
activating NK cell receptors NKG2D (Dunn et al., 2003; Guma et al., 2006; Welte et al., 
2003) and NKp30 as shown here. This would restore the equilibrium of activating and 
inhibitory signals on the target cell and protect the infected cells from being lysed. The 
modulation of NKp30L may therefore represent another strategy which contributes to the 
successful immune evasion of HCMV. 
 
D.3 Characteristics and Identification of NKp30L 
 
D.3.1 Heparan sulfate is not the ligand for NKp30 
 In a first attempt to establish the role of heparan sulfate as NKp30L, CHO cells were 
compared to CHO from the laboratories of Hillary Warren and Angel Porgador in respect to 
NKp30-ILZ fusion protein binding. All three cell lines showed a high affinity for the fusion 
protein, while the respective xylosyltranferase mutant CHO pgsA745 only bound minor 
amounts of NKp30-ILZ. In this respect the results of (Warren et al., 2005) could not be 
reproduced as they could not observe differences in staining pattern for wt and mutant cells. 
But the results fitted well with what was published by (Bloushtain et al., 2004). To elucidate, 
whether the staining results for NKp30L would correlate with functional activation of NKp30, 
cytotoxicity assays were performed. Here, no difference in lytic activity could be seen. Both 
cell lines were killed in a NKp30 dependent manner as demonstrated by blocking with anti-
NKp30 antibodies. This result is contradictory to the NKp30 fusion protein binding assays but 
has also been observed by (Warren et al., 2005). The contradicting results can probably 
partly be explained by a evolutionary difference in the cell surface structures between  
hamsters and humans. A second reason might be that NKp30-ILZ fusion proteins also bind 
polysaccharide structures and therefore produce high background stainings on CHO cells. 
Due to these opposing results it was decided to abandon CHO cells as a model system and 
concentrate on human cells as a more suitable model.  
 Here, the role of heparan sulfate as NKp30L was established using FACS-based as 
well as functional assays. Neither addition of heparan sulfate in blocking concentrations nor 
digestion of heparan sulfate residues from the cell surface could alter fusion protein binding 
or NKp30 dependent NK cell activity. As the heparan sulfate concentration used was 
sufficient to block binding of an anti-heparan sulfate antibody to the cell surface it should also 
have blocked NKp30 binding if it was a specific ligand for this receptor. The same is true for 
heparinase III digestion of cell surface heparan sulfate residues. Removal of these structures 
did not lead to a reduced NK cell activity.Therefore it is very unlikely that heparan sulfate is 
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the functional activating ligand for NKp30. A possible role as a co-ligand cannot be excluded. 
As the structure of NKp30 has not been solved yet there is no good possibility to predict 
ligand specificity of NKp30 through computational models.  
 
D.3.2 NKp30L involves a cell cycle regulated protein component 
 Trypsinization of Hek-293T cells did not only reduce binding of NKp30-ILZ fusion 
proteins but also activation of NK cells through NKp30. NKp30L expression on the cell 
surface as determined by fusion protein staining was almost completely restored to normal 
levels within four hours after trypsin treatment. This effect can be explained by a rather high 
turnover rate of the putative ligand. Additional data was obtained with experiments conducted 
with Jurkat cells and GPI-deficient mutants of this cell line. Both the wt and mutant cells 
showed expression of NKp30L on their surface (data not shown). Therefore it can be 
concluded that at least one proteinacious component has to be involved in linking NKp30L to 
the cell surface and that NKp30L does not involve a GPI-anchored protein.  
 With the help of the inhibitors colchicine and nocodazole Hek-293T cells could 
effienciently be arrested in M-phase of the cell cyle (Fig. 22 A). NKp30-ILZ fusion protein 
binding was significantly reduced in mitotic cells as compared to control treated cells. This 
would mean that NKp30L is downregulated during mitosis. It has been shown that NK cells 
show increased surveillance of mitotic cells and that this increased affinity depends on 
engagement of NKp46 (Nolte-'t Hoen et al., 2007). However, it seems probable that different 
NK cell ligands are cell cycle regulated in different ways such as to keep homeostasis 
between different activating and inhibiting stimuli. Progression into mitosis leads to major 
changes within the cell that also include membrane structure and dynamics. Membrane 
traffic and thus protein turnover is stalled almost completely (Warren, 1993). Possibly this 
would also affect NKp30L distribution on the cell surface. Another alternative would be that 
NKp30L regulation is coupled to the cell cycle machinery whose components are turned on 
and off in cyclic order during cell cycle progression. It will be interesting to further investigate 
the mechanism of cell cycle regulation of NKp30L and its implications for NK cell activation. 
 
D.3.3 Identification of NKp30L through an siRNA library 
 Many attempts to identify NKp30L have failed so far. It seems that common methods 
do not yield valuable results in this respect. In contrast, the rather new method of unbiased 
screening employing RNAi have lead to the discovery of new signaling pathways and 
proteins (Hattori et al., 2007). Therefore, an siRNA screen was conducted to identify the 
putative NKp30L. After transduction of EM3 cells with a library of shRNAs packaged in 
lentiviral particles, cells with impaired NKp30L expression were enriched. Using reverse 
transcription and nested PCR the shRNA sequences could be rescued from the transduced 
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cells. 
 Analysis of the enriched siRNA sequences was done on two different tracks. On the 
one hand single cell subclones were generated and the siRNAs expressed in single cells 
were amplified and sequenced. The second, more global approach was conducted using 
microarray analysis.  
 Sequencing of subclones turned out to be rather inefficient as shRNA structures are 
difficult to sequence and a single mutated or falsely inserted base pair would bias the results 
obtained with BLAST analysis. Apart from these technical problems, analysis of a small 
number of subclones cannot be considered representative of a whole cell population. It could 
merely serve as a control to the microarray experiment. However, some intracellular proteins 
could be identified that might be involved in the regulation of NKp30L expression.   
 As the siRNAs were designed to fit the affimetrix genechips it was possible to analyze 
the overall representation of each siRNA within the whole population. About 300-500 siRNA 
sequences were found to be significantly enriched within the population with impaired 
NKp30L expression. Of these, the candidate siRNAs that had the highest expression 
compared to the control population were determined. Then, several of the most promising 
targeted proteins that might play a role in NKp30L expression or regulation were selected. 
When comparing the data obtained from the microarray analysis to the data from the 
sequencing experiment, it became evident that some siRNAs had been discovered in both 
approaches. But this was not the case for all sequences. It seems that sequencing of a few 
subcloned siRNAs leads to a more randomized result and does not yield as evaluable and 
reproducible datasets as the microarray does. Nevertheless, the recovery of similar targets 
from both approaches serves as mutual confirmation of the methods used. But because a 
microarray provides a bigger and more reliable source of information it was decided to 
concentrate on the evaluation of the data obtained with this method. 
 Many of the siRNAs found to be enriched were directed against intracellular 
molecules. This is not surprising as a whole armada of molecules is involved in the 
expression or modification of a protein. Among the targeted sequences were DNA binding 
proteins such as transcription factors or DNA methyl transferases. Proteins associated with 
the cytoskeleton were also identified and interestingly also a valyl-tRNA synthetase. These 
molecules are all likely to be involved in NKp30L expression and secretion, but as the 
discovery of a functional NKp30L is most important, membrane proximal and transmembrane 
proteins were analyzed. 
 Of all the sequences identified, the siRNA directed against dystonia-1 or torsin-A was 
most highly enriched in the NKp30L depleted cell population. Although this is not a 
membrane proximal protein it is nevertheless interesting as this was by far the most enriched 
siRNA. A mutation of torsin-A is discussed to promote an illness called early onset torsion 
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dystonia. The mutation causes the protein to aggregate in perinuclear inclusions as opposed 
to the endoplasmic reticulum localization of the wild-type protein (Ozelius et al., 1997). It 
seems that functional torsin-A acts as a chaperone in the ER and is involved in protein 
folding and secretion (Caldwell et al., 2003). Most of the available data concentrates on 
expression of torsin-A and its mutant isoform in the brain but actually torsin-A is widely 
expressed throughout the body with a yet undescribed function there. As a member of the 
family of AAA+ ATPases its function might be related to the assembly and disassembly of 
protein complexes (Hanson and Whiteheart, 2005). This putative function might also explain 
why this protein was found on top of the hit list. It is improbable that torsin-A constitutes 
NKp30L but it might be very important for its transport to the cell surface or maybe for the 
assembly of the NKp30L complex.  
 Interleukin-32 (IL-32) was first described as transcript termed NK4 (Dahl et al., 1992) 
expressed in NK cells and T cells. However, recent data suggest that IL-32 is also strongly 
expressed in epithelial cells and EBV-infected B-lymphocytes (Carter et al., 2002; Kim et al., 
2005). No definitive function has been assigned to IL-32 until now. Although it can be 
secreted as a proinflammatory cytokine, it has been described that most of the IL-32 protein 
is found in the cytoplasm. There, it might be involved in promotion of cell death, as cells 
transfected to express IL-32 mRNA undergo apoptosis (Goda et al., 2006). A possible 
mechanism by which IL-32 could function as a proinflammatory cytokine might be release of 
a membrane bound form of IL-32 by proteinase 3. This enzyme has been shown to bind and 
cleave IL-32 (Novick et al., 2006). As there is so little information on IL-32 and its function, it 
might well play a role as NKp30L or enhancing NKp30 signaling when secreted or presented. 
NK cells are highly important in the control of herpesviral infections. Hence, it would be 
possible that the secretion of IL-32 of EBV-infected B-lymphocytes provides a danger signal 
to NK cells and activates them. 
 Telencephalin or ICAM5 is expressed exclusively in the brain, specifically in the 
telencephalon. There, it has a crucial function in neuronal development (Furutani et al., 
2007). It seems unlikely that a neuronal protein might be involved in NK cell function. In a 
healthy host NK cells cannot cross the blood-brain-barrier. Furthermore, ICAM5 probably 
won’t be expressed in EM3 cells. The two siRNAs identified in the screen presumably lead to 
off-target effects. As the family of ICAM proteins shows a high similarity among each other it 
is possible that the recovered siRNA also had an effect on other ICAM molecules which play 
an important role for lymphocyte adhesion. It has already been shown that ICAM molecules 
bind to the receptor LFA-1 (Makgoba et al., 1988). Although this does not exclude the 
existence of further receptors for ICAM proteins together with the exisiting data it is 
implausible that NKp30 constitutes a specific receptor for an ICAM molecule.  
 CD151 belongs to the rather young family of tetraspanins. These very small proteins 
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are characterized by four transmembrane domains and conserved cysteine residues forming 
crucial disulfide bonds. Together with integrins, tetraspanins build signaling platforms similar 
to, but functionally distinct from lipid rafts. As an integrin partner, CD151 modulates integrin-
dependent cell morphology, migration, signalling and adhesion strengthening (Hemler, 
2005). Mutation of CD151 resulting in a truncated protein leads to hereditary nephritis and a 
certain kind of skin blistering disease (Karamatic Crew et al., 2004). This finding stresses the 
importance of tetraspanins in basement membranes. CD151 has also been implicated in cell 
motility and tumor progression (Liu et al., 2007). Taken together this molecule might be an 
interesting candidate as ligand for NKp30. As this molecule is linked to tumor invasion of 
healthy tissues supervision of this marker by NK cells seems plausible.  
 HLA-B associated transcript-3 (BAT3) or scythe is found among the genes of the 
MHC cluster, specifically in the MHC III region. It does not show any homology to the 
common MHC proteins but contains many proline rich sequences. Although BAT3 has been 
postulated as an NKp30 ligand earlier at the 10th meeting of the society for natural 
immunology in 2007, no data has been published on that behalf yet. Full length BAT3 seems 
to be involved in several processes concerning apoptosis. Hsp70 can be inhibited by BAT3 
(Thress et al., 2001). BAT3 can also serve as a substrate for caspase 3  (Wu et al., 2004). A 
BAT3 knockout mouse showed severe developmental defects which can be ascribed to 
dysregulation of apoptosis and proliferation (Desmots et al., 2005). Another interesting 
finding is that BAT3 in cancerous tissue is expressed in a splice variant different from the one 
found in healthy tissue (Roy et al., 2005). This could provide a mechanism through which a 
normal cell can be distinguished from a healthy cell. Further information on the activity of this 
protein is scarce and questionable. The position of the BAT3 gene in the MHC locus might 
point to a function in the immune system that has not yet been elucidated. These facts 
request that BAT3 should be explored as a possible ligand of NKp30. 
 The gene for LYZL6 has been discovered in a screen for lysozyme homologues 
(Zhang et al., 2005). Similar to the original lysozyme, LYZL6 seems to be a secreted protein 
and has retained its catalytic ability to hydrolyse glycosidic bonds. Its expression is limited to 
the testis/epididymis tissue, which makes it unsuitable as a possible NKp30L candidate. In 
this case a cross-reactivity of the respective siRNAs cannot be excluded although it might 
also be the case that due to the very limited information on this protein a more widespread 
distribution on stressed cells is possible. Because the gene for LYZL6 is situated within a 
chemokine cluster (Nomiyama et al., 1999) an immunological function appears feasible but 
not necessarily that of an NKp30 ligand. 
 A very interesting result of this screen was that several molecules of the MHC region 
came up on top of the list. These included not only BAT3, a member of the MHC III family, 
but also HLA-C, a MHC I molecule. This is an intriguing finding as NK cells are known to bind 
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MHC molecules with their inhibitory KIR receptors as discussed in the introduction. It would 
be interesting to speculate that such an important family of activating NK cell receptors as 
the NCR might bind to MHC related molecules. The interaction of NK cells with MHC 
molecules seems to be much more complex as previously thought. Several new mechanisms 
have just been discovered. For example, during the contact of the NK cell with the target cell 
ligands for various NK cell receptors includig MHC molecules are transferred from the target 
cell onto the NK cell surface. The detailed mechanism and outcome of this process are still 
being discussed (Caumartin et al., 2007; Williams et al., 2007). Hence, it might well be 
possible that NKp30 recognizes certain epitopes presented by MHC molecules in trans or in 
cis. It has also been described that MHC II molecules associated with tetraspanin signaling 
platforms serve a different functional purpose and present distinct peptide epitopes 
(Kropshofer et al., 2002). Besides, soluble MHC I molecules have been implicated in 
initiating apoptotic events in NK cells that could be reverted by engagement of KIR receptors 
(Spaggiari et al., 2002).  
 Taking into consideration the most interesting hits of the siRNA screen, the ligand for 
NKp30 presumably is build up within a tetraspanin based signaling platform and could 
involve molecules originating from genes found within the MHC locus. As NKp30 should be 
able to detect abnormal or transformed cells it might recognize differentially spliced isoforms 
of proteins such as BAT3 and others that arise upon progression to cancer.  
 The results of this screen will be subjected to further investigation. To this end, the 
function of single siRNAs and their impact on NKp30L expression will be evaluated in EM3 
cells. It is also necessary to exclude off-target effectes of the respective siRNAs. If positive 
results from the screen can be confirmed and siRNAs prove to be specific, the resulting 
target molecules will be examined for their possible function as NKp30L.  
As NKp30 has been discovered several years ago and its ligand has been sought 
after since then, it is unlikely that the answer will be a simple one. While our knowledge of 
intercellular interactions becomes more and more complex and involves an ever growing list 
of molecules it seems that NKp30 offers the opportunity to add to this list a whole new 
mechanism of interaction. It is still unlikely that a ubiquitously present structure such as 
heparan sulfate would suffice to unleash the perilous powers of an NK cell. Elucidating the 
functional cellular ligand for NKp30 will constitute a major advance in the field of innate 
immunology. This thesis has laid the foundation for the discovery of NKp30L and its mode of 
function. 
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ADCC   antibody-dependent cellular cytotoxicity 
AIDS   aquired immunodeficiency syndrome 
BAC   bacterial artificial chromosome 
CD   cluster of differentiation 
CEACAM1  carcinoembryogenic antigen cellular adhesion molecule 1 
DC   dendritic cell 
E.coli   Escherischia coli 
EBV   Epstein-Barr-virus 
ER   endoplasmic reticulum 
FACS   fluorescence-activated cell sorting 
Fig.   figure 
GPI   glycosyl-phosphatidylinositol 
h   hour 
HCMV  human cytomegalovirus 
HFF   human foreskin fibroblast 
HIV   human immunodefiency virus 
HLA   human leukocyte antigen 
Ig   immunoglobulin 
IL   interleukin 
ILZ   isoleucin-zipper 
ITAM   immunoreceptor tyrosine-based activation motif 
ITIM   immunoreceptor tyrosine-based inhibition motif 
ITSM    Immunoreceptor tyrosine-based switch motif 
kbp   kilo base pairs 
KIR   killer cell Ig-like receptor 
MAP   mitogen activated protein 
MHC I   major histocompatibility complex class I 
NCR   natural cytotoxicity receptor 
NK cell   natural killer cell 
NKC   NK gene complex 
NKp30L  NKp30 ligand 
PCR   polymerase chain reaction 
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PI   propidium iodide 
PI3K   phosphatidylinositol-3 kinase 
PLCγ   phospholipase C γ 
PTK   protein tyrosine kinase 
RT   reverse transcription 
SHP   SH2 domain containing phosphatase 
SIGLEC  sialic-acid-binding immunoglobulin-like lectin 
SRR   SLAM-related receptors 
TNF-α  tumor necrosis factor α 
ULBP   UL16 binding protein 
 
The single amino acid code was used to describe amino acid residues. 
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